Methods of detection for engineered cells

HK40137529APending Publication Date: 2026-09-11ALLOGENE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026127127
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-20
Filing Date
2026-08-06
Publication Date
2026-09-11

Smart Images

  • Figure 00000104_0000
    Figure 00000104_0000
  • Figure 00000129_0000
    Figure 00000129_0000
  • Figure 00000130_0000
    Figure 00000130_0000
Patent Text Reader

Abstract

Provided herein are methods for detecting the expression of different bicistronic-expressed polypeptides, such as chimeric cytokine receptors, that have been engineered into a population of immune cells (e.g., a population of CAR T cells). In one aspect, the disclosure provides in vitro methods of detecting bicistronic expressed polypeptides in chimeric antigen receptor (CAR) T cells.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480040531.5 (22) Application Date 2024.06.20 (30) Priority Data 63 / 509070 2023.06.20 US (85) PCT International Application Entering National Phase Date 2025.12.17 (86) PCT International Application Application Data PCT / US2024 / 034723 2024.06.20 (87) PCT International Application Publication Data WO2024 / 263710 EN 2024.12.26 (71) Applicant: Elogi Therapeutics Company Address: California, USA (72) Inventor: Xie Fei R.J. Lin (74) Patent Agency: China Patent Agency (Hong Kong) Limited 72001 Patent Attorney Quan Lujun Zhang Hua (51) Int.Cl. G01N 33 / 53 (2006.01) A61K 35 / 17 (2006.01) C07K 14 / 715 (2006.01) (54) Invention Title: Method for Detection of Engineered Cells (57) Abstract This invention provides a method for detecting the expression of various bicistronic expressed peptides, such as chimeric cytokine receptors, said bicistronic expressed peptides having been engineered into a population of immune cells (e.g., a CAR T cell population). In one aspect, this disclosure provides an in vitro method for detecting bicistronic expressed peptides in chimeric antigen receptor (CAR) T cells. Claims 2 pages, Description 84 pages, Drawings 9 pages, CN 121532650 A 2026.02.13 CN 1 21 53 26 50 A 1. An in vitro method for detecting a bicistronic expressed polypeptide in chimeric antigen receptor (CAR) T cells, the method comprising: a) contacting the CAR T cells with an exogenous drug agent, wherein the CAR T cells contain a polynucleotide expressing the bicistronic expressed polypeptide, a linker peptide, and a further polypeptide, wherein the linker peptide is located at the C-terminus of the bicistronic expressed polypeptide; and b) detecting the linker peptide after step a) thereby indicating the presence of the bicistronic expressed polypeptide in the CAR T cells. 2. The method of claim 1, wherein the bicistronic expressed polypeptide comprises a transmembrane domain. 3. The method of claim 1, wherein the bicistronic expressed polypeptide is a membrane protein comprising a transmembrane domain. 4. The method of claim 2 or 3, wherein the bicistronic expressed polypeptide further comprises an intracellular domain. 5. The method of any one of claims 1-4, wherein the linker peptide is located at the C-terminus of the bicistron-expressed polypeptide.6. The method of any one of claims 3-5, wherein the linker peptide is located at the C-terminus of the intracellular domain. 7. The method of any one of claims 1-6, wherein the bicistronic expressed polypeptide further comprises an extracellular domain. 8. The method of any one of the preceding claims, wherein the linker peptide is heterologous to the bicistronic expressed polypeptide. 9. The method of any one of claims 4-8, wherein the linker peptide is adjacent to the intracellular domain of the bicistronic expressed polypeptide. 10. The method of any one of claims 4-9, wherein the intracellular domain is an intracellular signal transduction domain. 11. The method of any one of claims 1-10, wherein the additional polypeptide is a CAR. 12. The method of any one of the preceding claims, wherein the exogenous agent is selected from small molecule reagents and target molecules, wherein the CAR specifically binds to the target molecule. 13. The method of claim 12, wherein the small molecule reagent stimulates cytokine production in the CAR T cells. 14. The method of claim 12 or 13, wherein the small molecule reagent comprises phorbol myristate acetate (PMA) and / or ionomycin. 15. The method of claim 12, wherein the target molecule is a soluble target molecule. 16. The method of claim 12, wherein the target molecule is expressed on the surface of the target cell. 17. The method of claim 16, wherein the contacting comprises contacting the CAR T cell with the target cell. 18. The method of claim 16 or 17, wherein the target cell is an inactivated target cell. 19. The method of claim 15, wherein the contacting step comprises contacting the CAR T cell with the soluble target molecule. 20. The method of any of the preceding claims, wherein the linker peptide is cleavable. 21. The method of claim 20, wherein the linker peptide is enzymatically cleavable. 22. The method of claim 20, wherein the linker peptide is a self-cleaving peptide. 23. The method of claim 22, wherein the self-cleaving peptide is a P2A or T2A peptide. 24. The method of any of the preceding claims, wherein the linker peptide comprises the amino acid sequence shown in any one of SEQ ID NO: 305-320. 25. The method of any of the preceding claims, wherein the bicistronic expressed polypeptide is a chimeric cytokine receptor (CCR), wherein the CCR comprises a transmembrane domain and an intracellular domain. 26. The method of claim 25, wherein the CCR further comprises an extracellular domain. 27. The method of claim 25, wherein the CCR does not comprise an extracellular domain.28. The method of claim 25 or 26, wherein the CCR is an inducible CCR. 29. The method of any one of claims 25-27, wherein the CCR is a constitutively active CCR. 30. The method of any one of the preceding claims, wherein the detection step comprises detecting the linker peptide by flow cytometry and / or Western blotting. 31. The method of claim 8, wherein the bicistronic expressed polypeptide further comprises an intracellular domain. 32. The method of claim 31, wherein the linker peptide is located at the C-terminus of the intracellular domain. 33. An in vitro method for analyzing a CAR T cell population, wherein the CAR T cells express a bicistronic expressed polypeptide, a linker peptide, and CAR, the method comprising: a) contacting a sample of the CAR T cell population with an exogenous drug agent; and b) detecting the bicistronic expressed polypeptide in the sample after the contacting step. 34. The method of claim 33, wherein the linker peptide is attached to the C-terminus of the bicistronic expressed polypeptide, and the step of detecting the bicistronic expressed polypeptide includes detecting the linker peptide in the sample. 35. The method of claim 33 or 34, further comprising: c) analyzing whether a predetermined level or more of the bicistronic expressed polypeptide is detected in the sample. 36. The method of claim 35, wherein the predetermined level is the presence of the linker peptide in at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50% of the CAR T cells in the sample. 37. The method of any one of claims 33-36, wherein the CAR T cell population constitutes a CAR T cell drug substance or a CAR T cell drug product. 38. The method of claim 37, further comprising: d) if a predetermined level or more of the bicistronic expressed polypeptide is detected in the sample, formulating the CAR T cell population to form a drug product; and optionally e) freezing the drug product. Claims 2 / 2 Page 3 CN 121532650 A Method for Detecting Engineered Cells Cross-Reference to Related Applications

[0001] This application claims priority to U.S. Provisional Application No. 63 / 509,070, filed June 20, 2023, the contents of which are incorporated herein by reference in their entirety.

[0002] Sequence List This application contains a sequence list electronically filed in XML format and incorporated herein by reference in its entirety. The electronic file was created on June 14, 2024, and is entitled “AT-061 / 02WO_ST26.xml”, with a size of 533,947 bytes. Background Art

[0003] Adoptive transfer of genetically modified immune cells to recognize tumor-associated antigens is showing promise as a novel approach to cancer treatment (see, for example, Brenner et al., Current Opinion in Immunology, 22(2): 251-257 (2010); Rosenberg et al., Nature Reviews Cancer, 8(4): 299-308 (2008)). Immune cells can be genetically modified to express chimeric antigen receptors (CARs), which are fusion proteins consisting of an antigen recognition portion and a T cell activation domain (see, for example, Eshhar et al., Proc. Natl. Acad. Sci. USA, 90(2): 720-724 (1993)). CAR-containing immune cells (e.g., CAR-T cells (CAR-T)) are engineered to confer antigen specificity while maintaining or enhancing their ability to recognize and kill target cells.

[0004] T cell proliferation, cytotoxic potency, and persistence are driven by signal transduction pathways. Conventional CAR designs provide two signals: CD3ζ activation (signal 1) and co-stimulation (signal 2, e.g., via expression of 4-1BB, OX40, and / or CD28). In some contexts, a third signal (signal 3) may be desired, namely cytokine-induced cytokine receptor signaling (e.g., cytokine support for immune enhancement). However, some methods for providing signal 3 (e.g., systemic infusion of recombinant cytokines / cytokine mimics) have encountered significant limitations, such as systemic toxicity in humans. Alternative approaches include engineering immune cells (e.g., CAR T cells) to express chimeric cytokine receptors (CCRs), as described in US2019-0292533A1, US2020-0291090A1, US2020-0276238A1, and US2021-0061881A1, each of which is incorporated herein by reference in its entirety. Improvements to CAR-T cell therapy via the use of additional non-CAR peptides (such as CCR) (e.g., improved efficacy and / or accuracy) will benefit the patient community.

[0005] There is a need for methods to detect the expression of peptides (e.g., chimeric cytokine receptors) that have been engineered into immune cell populations (e.g., CAR T cell populations) with different bicistronic expression. This document provides compositions and methods to address this need. Summary of the Invention

[0006] In one aspect, this disclosure provides an in vitro method for detecting bicistronic expressed peptides in chimeric antigen receptor (CAR) T cells. In one embodiment, the method includes the step of contacting the CAR T cells with an exogenous drug agent. In another embodiment, the CAR T cells comprise the bicistronic expressed peptide, a linker peptide, and other...The linker peptide is a polynucleotide of the polypeptide outside the cell. In some embodiments, the linker peptide is located at the C-terminus of the bicistronic expressed polypeptide. In another embodiment, the method further includes a step of detecting the linker peptide after the contact step. In another embodiment, the detection of the linker peptide indicates the presence of the bicistronic expressed polypeptide in the CAR T cells. Specification 1 / 84 page 4 CN 121532650 A

[0007] In other embodiments, the bicistronic expressed polypeptide comprises a transmembrane domain, or is a membrane protein comprising a transmembrane domain. In one embodiment, the bicistronic expressed polypeptide further comprises an intracellular domain. In another embodiment, the linker peptide is located at the C-terminus of the bicistronic expressed polypeptide, or the linker peptide is located at the C-terminus of the intracellular domain. In other embodiments, the bicistronic expressed polypeptide further comprises an extracellular domain. In one embodiment, the linker peptide is heterologous to the bicistronic expressed polypeptide. In another embodiment, the linker peptide is adjacent to the intracellular domain of the bicistronic expressed polypeptide. In another embodiment, the intracellular domain is an intracellular signal transduction domain. In some embodiments, the additional polypeptide is a CAR.

[0008] In another embodiment, the exogenous agent used in the contacting step is selected from small molecule reagents and target molecules, wherein the CAR specifically binds to the target molecule. In other embodiments, the small molecule reagent stimulates cytokine production in the CAR T cells. In another embodiment, the small molecule reagent includes phorbol myristate acetate (PMA) and / or ionomycin. In one embodiment, the target molecule is a soluble target molecule, or the target molecule is expressed on the surface of the target cell. In another embodiment, the contacting step includes contacting the CAR T cell with the target cell. In other embodiments, the target cell is an inactivated target cell. In other embodiments, the contacting step includes contacting the CAR T cell with the soluble target molecule. In one embodiment, the linker peptide is cleavable. In one embodiment, the linker peptide can be cleaved by an enzyme. In other embodiments, the linker peptide is a self-cleaving peptide. In one embodiment, the self-cleaving peptide is a P2A or T2A peptide. In another embodiment, the linker peptide comprises the amino acid sequence shown in any one of SEQ ID NO: 305-320. In another embodiment, the bicistronic expressed polypeptide is a chimeric cytokine receptor (CCR). In one embodiment, the CCR comprises a transmembrane domain and an intracellular domain. In another embodiment, the CCR further comprises an extracellular domain, orThe CCR does not contain an extracellular domain. In one embodiment, the CCR is an inducible CCR, or the CCR is a constitutively active CCR (CACCR). In one embodiment, the CCR is a CACCR without an extracellular domain.

[0009] In another embodiment, the detection step includes detecting the linker peptide by flow cytometry and / or Western blotting.

[0010] In another aspect, this disclosure provides an in vitro method for analyzing a CAR T cell population, wherein the CAR T cells express a bicistronic expressed polypeptide, a linker peptide, and CAR. In one embodiment, the method includes contacting a sample of the CAR T cell population with an exogenous agent. In other embodiments, the method further includes detecting the bicistronic expressed polypeptide in the sample after the contacting step. In one embodiment, the linker peptide is attached to the C-terminus of the bicistronic expressed polypeptide. In other embodiments, the step of detecting the bicistronic expressed polypeptide includes detecting the linker peptide in the sample. In another embodiment, the method further includes the step of analyzing whether a predetermined level or more of the bicistronic expressed polypeptide is detected in the sample. In one embodiment, the predetermined level is the presence of the linker peptide in at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50% of the CAR T cells in the sample. In other embodiments, the CAR T cell population constitutes a CAR T cell drug substance or a CAR T cell drug product. In one embodiment, the method further includes the step of formulating the CAR T cell population to form a drug product if a predetermined level or more of the bicistronic expressed polypeptide is detected in the sample. In another embodiment, the method includes the step of freezing the drug product. Specification 2 / 84 pages 5 CN 121532650 A Brief Description of the Drawings

[0011] Figures 1A-1C show the following schematic diagrams: the engineered constitutively active chimeric cytokine receptor (CACCR) of this disclosure (A) and the vector (B-C) for CACCR expression.

[0012] Figures 2A and 2B show the staining of cells with anti-idiotype antibodies against anti-CD19 at 24 hours (A) and 48 hours (B) as measured by flow cytometry.

[0013] Figures 3A and 3B show the staining of cells with anti-idiotype antibodies against anti-CD19 and anti-P2A antibodies, with or without incubation with CD19-Fc (A) or irradiated cells (B), as measured by flow cytometry.

[0014] Figure 4 shows the detection of P2A in engineered immune cells using Western blotting.

[0015] Figure 5 shows the manufacturing workflow for engineered immune cells (e.g., CAR T cells).

[0016] Figures 6A-6B show CCR detection in P+I stimulated and unstimulated samples. Detailed Description

[0017] This disclosure provides methods for identifying and / or detecting bicistronic expressed peptides in engineered immune cells (e.g., chimeric antigen receptor (CAR) cells). In one embodiment, the method includes the step of contacting the engineered immune cells with an exogenous pharmaceutical agent. In another embodiment, the engineered immune cells comprise a polynucleotide sequence expressing a bicistronic expressed peptide, a linker peptide, and additional peptides. In another embodiment, the linker peptide is located at the C-terminus or N-terminus of the bicistronic expressed peptide. In other embodiments, the method further includes the step of detecting the linker peptide after the contact step, thereby indicating the presence of the bicistronic expressed peptide in CAR T cells.

[0018] Unless otherwise specified, practice of this disclosure will employ conventional techniques of molecular biology (including recombinant technologies), microbiology, cell biology, biochemistry, and immunology, which are within the scope of the art. These techniques are well explained in the literature, such as: *Molecular Cloning: A Laboratory Manual*, 2nd edition (Sambrook et al., 1989), Cold Spring Harbor Press; *Oligonucleotide Synthesis* (edited by M.J. Gait, 1984); *Methods in Molecular Biology*, Humana Press; *Cell Biology: A Laboratory Notebook* (edited by J.E. Cellis, 1998), Academic Press; *Animal Cell Culture* (edited by R.I. Freshney, 1987); *Introduction to Cell and Tissue Culture* (JP Mather and PE Roberts, 1998), Plenum Press; *Cell and Tissue Culture: Laboratory Procedures* (edited by A. Doyle, J.B. Griffiths, and D.G. Newell, 1993–1998), J. Wiley and Sons; *Methods in Enzymology* (Academic Press, Inc.); *Handbook of Experimental...Immunology (edited by D.M. Weir and C.C. Blackwell); Gene Transfer Vectors for Mammalian Cells (edited by J.M. Miller and M.P. Calos, 1987); Current Protocols in Molecular Biology (edited by F.M. Ausubel et al., 1987); PCR: The Polymerase Chain Reaction (edited by Mullis et al., 1994); Current Protocols in Immunology (edited by JE Coligan et al., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (edited by C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practical approach (edited by D. Catty, IRL Press, 1988–1989); Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean (eds., Oxford University Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and manual, 3 / 84 pages, 6 CN 121532650 A JD Capra (eds.), Harwood Academic Publishers, 1995). For example, gene editing technologies using TALENs, CRISPR / Cas9, and megaTAL nucleases are within the scope of the art and are well explained in the literature, such as T. Gaj et al., Genome-Editing Technologies: Principles and Applications, Cold Spring Harb Perspect Biol 2016;8:a023754 and citations therein.

[0019] DefinitionsAs used herein, the terms “a” and “an” are used to mean one or more. For example, references to “cell” or “antibody” mean “one or more cells” or “one or more antibodies”.

[0020] As used herein, “autologous” means that the cells, cell lines, or cell populations used to treat a subject are obtained from said subject.

[0021] As used herein, “allogeneic” means that the cells or cell populations used to treat a subject are not obtained from said subject, but from a donor.

[0022] As used herein, “bicistronic expressed polypeptide” means a polypeptide encoded by a first nucleic acid sequence, which is present in a polynucleotide or expression vector / expression cassette together with a second nucleic acid sequence encoding at least a second polypeptide, wherein said first nucleic acid sequence and second nucleic acid sequence are present as consecutive nucleic acid sequences in the polynucleotide or vector. For bicistronic expression, the polynucleotide or expression vector / cassette includes a nucleic acid sequence encoding a ribosomal jumping sequence, such as, but not limited to, sequences encoding self-cleaving peptides (e.g., 2A peptides, including P2A, T2A, E2A, and F2A peptides). These peptides (identified in the aphthovirus subgroup of small RNA viruses) cause the ribosome to "jump" from one codon to the next, but no peptide bond is formed between the two amino acids encoded by said codon. A "codon" refers to three nucleotides on mRNA (or on the sense strand of a DNA molecule) that are translated by the ribosome into one amino acid residue. Thus, two polypeptides can be synthesized from a single, consecutive open reading frame within mRNA, separated by a 2A oligopeptide sequence within the frame. This type of ribosomal jumping mechanism is well known in the art and is known to be used by several vectors for expressing several proteins encoded by a single messenger RNA.

[0023] As used herein, the term "labeler" generally refers to an agent capable of interacting with cellular components, including but not limited to molecules on and / or within the cell membrane, and intracellular molecules of the cell. The interaction between the agent and the cellular component can be covalent or non-covalent, reversible or irreversible. The labeler can be specific to cellular components, including but not limited to cellular biomolecules (e.g., peptides, nucleic acids, lipids, etc.). In some embodiments, the labeler can be an agent specific to a biological target, such as an antibody or antibody fragment. In one embodiment, the labeler is an agent specific to cell surface molecules (e.g., cell surface proteins or cell membrane proteins). In some cases, the labeler may include one or more detectable labels. In some embodiments, the labeler comprises an antibody, which optionally conjugates to a detectable label.

[0024] In some implementations, the detectable label is selected from the group consisting of: fluorescent labels, photochromic compounds, protein fluorescent labels, molecules capable of colorimetric reactions, magnetic labels, radioactive labels, oligonucleotide labels, and haptens. In some implementations, the fluorescent label is selected from the group consisting of: Atto dyes, Alexafluor dyes, quantum dots, hydroxycoumarins, aminocoumarins, methoxycoumarins, Cascade Blue, Pacific Blue, Pacific Orange, firefly yellow, NBD, R-phycoerythrin (PE), PE-Cy5 conjugate, PE-Cy7 conjugate, Red 613, PerCP, TruRed, FluorX, luciferin, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-rhodamine, rhodamine B, Texas Red, allophycocyanin (APC), APC-Cy7 conjugate, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutant), GFP (Y66F mutant), EBFP, EBFP2, Azurite, GFPuv, T- Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, Specification 4 / 84 pages 7 CN 121532650 A TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild-type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (RFP), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoerythrin (BPE), mCherry, HcRed1, Katusha, P3, polydinoflavin chlorophyll (PerCP), mKate (TagFP635)TurboFP635, mPlum, and mRaspberry. In some embodiments, one or more labelers are used in flow cytometry. One or more labelers may be directly or indirectly conjugated or conjugated to the labeler. In the indirect form, one or more labelers may be conjugated or conjugated to a molecule capable of binding to the labeler. For example, the labeler may be conjugated to an oligonucleotide sequence complementary to another oligonucleotide sequence derived from an oligonucleotide conjugated to the labeler (e.g., an antibody conjugated to an oligonucleotide). In the case of a binder (such as a secretory molecule binder, e.g., a secretory cytokine binder), the labeler may also be used with the methods and compositions of this disclosure.

[0025] As used herein, “immune cell” means a hematopoietic cell that is functionally involved in the initiation and / or execution of innate and / or adaptive immune responses. Examples of immune cells include T cells (e.g., α / β T cells and γ / δ T cells, regulatory T (Treg) cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes.

[0026] As used herein, the term “expression” refers to the transcription and / or translation of a specific nucleotide sequence driven by a promoter.

[0027] As used herein, “expression vector” refers to a vector containing a recombinant polynucleotide that includes an expression control sequence operatively linked to the nucleotide sequence to be expressed. Expression vectors include all those known in the art, including viscera, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) incorporating recombinant polynucleotides.

[0028] As used herein, “expression cassette” refers to one or more expression units of one or more coding sequences operatively linked to a promoter. In some embodiments, the expression of multiple coding sequences may be driven by a single promoter, and more than one coding sequence may be linked by a sequence encoding a 2A peptide (e.g., P2A or T2A). In some embodiments, the expression of multiple coding sequences is carried out by ribosome jumping. As an example, a bicistronic expression cassette allows the expression of two proteins from the same RNA transcript driven by a single promoter. In some implementations, the expression of multiple coding sequences can be driven by multiple promoters, each operatively linked to a coding sequence.

[0029] As used herein, a “functionally expressed” gene means a gene that is expressed and that expression produces a functional genetic end product. For example, if a gene encodes a protein, then the cell functionally expresses the gene if the expression of the gene ultimately produces a protein with an appropriate function. Thus, for example, if the gene is not transcribed, or the expression of the gene ultimately produces an untranslated or nonfunctional protein (e.g., the protein is not properly folded or is not transported to its site of action), the expression of the gene will not be functional.If the RNA is at a point (e.g., a membrane, for membrane-bound proteins), then the gene is not functionally expressed. Functional expression can be measured directly (e.g., by measuring the gene product itself) or indirectly (e.g., by measuring the effect of the gene product).

[0030] As used herein, the term “extracellular ligand-binding domain” refers to an oligopeptide or polypeptide capable of binding a ligand. Preferably, the domain will be capable of interacting with cell surface molecules. For example, the extracellular ligand-binding domain may be selected to recognize ligands used as cell surface markers on target cells associated with a specific disease state. The term “stalk domain” is used herein to refer to any oligopeptide or polypeptide that acts on a transmembrane domain linked to an extracellular ligand-binding domain. Specifically, the stalk domain is used to provide more flexibility and accessibility to the extracellular ligand-binding domain.

[0031] The term “intracellular signal transduction domain” refers to the portion of a protein that transduces effector signals and guides the cell to perform specialized functions.

[0032] As used herein, the term “exogenous” means any material introduced or generated from outside an organism, cell, tissue, or system. In some embodiments, the exogenous or recombinant sequence or the exogenous or recombinant protein is not a naturally occurring sequence or protein and is not endogenous or native to the cell, tissue, or organism.

[0033] The term “intracellular signal transduction domain” refers to a portion of a protein that transduces effector signals and directs the cell to perform specialized functions.

[0034] As used herein, the term “antigen-binding fragment” or “antigen-binding portion” of an antibody refers to one or more fragments of an intact antibody that retain the ability to specifically bind to a given antigen. The antigen-binding function of an antibody can be performed by fragments of an intact antibody. Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include Fab; Fab'; F(ab')2; Fd fragments consisting of VH and CH1 domains; Fv fragments consisting of VL and VH domains of a single arm of the antibody; single-domain antibody (dAb) fragments (see, for example, Ward et al., Nature 341:544-546, 1989); and isolated complementarity-determining regions (CDRs).

[0035] Antibodies, antibody conjugates, or peptides that "specifically bind" to a target are terms well understood in the art, and methods for determining such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" if its reaction or association with a particular cell or substance is more frequent, faster, longer-lasting, and / or has a greater affinity than its reaction or association with alternative cells or substances. An antibody is said to "specifically bind" to a target if its binding to a target has a greater affinity, is easier, and / or lasts longer than its binding to other substances. AlsoIt should be understood that, according to this definition, for example, an antibody (or part or epitope) that specifically binds to a first target may or may not specifically bind to a second target. Therefore, “specific binding” does not necessarily require (but may include) exclusive binding.

[0036] The “variable region” of an antibody refers to the variable region of a single or combined antibody light chain or the variable region of an antibody heavy chain. As is known in the art, the variable regions of the heavy and light chains each consist of four frame regions (FRs) connected by three complementarity-determining regions (CDRs), also known as hypervariable regions. The CDRs in each chain are held tightly together by the FRs and facilitate the formation of antigen-binding sites of the antibody with CDRs from the other chain. Several techniques are used to determine CDRs, such as those based on cross-species sequence variability (i.e., Kabat et al., Sequences of Proteins of Immunological Interest, (5th edition, 1991, National Institutes of Health, Bethesda MD)); methods based on crystallographic studies of antigen-antibody complexes (Al-lazikani et al., 1997, J. Molec. Biol. 273:927–948); and the Chothia system (i.e., Chothia and Lesk, J. Mol. Biol. (1987) 196(4):901–917). As used herein, a CDR may refer to a CDR defined by either or a combination of both methods.

[0037] The antibodies (and CARs) of this disclosure can be produced using techniques well known in the art, such as recombinant techniques, phage display techniques, synthetic techniques, or combinations of such techniques, or other techniques readily known in the art (see, for example, Jayaseena, SD, Clin. Chem., 45: 1628-50, 1999 and Fellouse, FA et al., J. Mol. Biol., 373(4): 924-40, 2007).

[0038] As is known in the art, “polynucleotide” or “nucleic acid” as used interchangeably herein refers to a nucleotide chain of any length and includes DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogs, or any substrate that can be incorporated into the chain by DNA or RNA polymerase. Polynucleotides may contain modified nucleotides, such as methylated nucleotides and their analogs. If present, modifications to the nucleotide structure may be conferred before or after chain assembly. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization, such as by conjugation to labeled components. Other types of modification include, for example, "caps"; analogues to oneSubstitution of one or more naturally occurring nucleotides; internucleotide modifications, such as those with non-electrolyte links (e.g., methylphosphonic acid esters, phosphate triesters, aminophosphate esters, carbamates, etc.) and those with charged links (e.g., thiophosphate esters, dithiophosphate esters, etc.), those containing pendant moieties (e.g., proteins, nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalating agents (e.g., acridine, psoralen, etc.), those containing chelating agents (e.g., metals, radioactive metals, boron, oxidizing metals, etc.), those containing alkylating agents, those with modified links (e.g., α-anomeric nucleic acids, etc.); and unmodified forms of one or more polynucleotides. Furthermore, any of the hydroxyl groups commonly present in sugars can be substituted (e.g., replaced by phosphonic acid groups, phosphate groups), protected by standard protecting groups, or activated to prepare additional links with other nucleotides, or can be conjugated to a solid support. The 5' and 3' terminal OH groups can be phosphorylated or partially substituted with an amine or an organic capping group of 1 to 20 carbon atoms. Other hydroxyl groups can also be derived as standard protecting groups. Polynucleotides can also contain similar forms of ribose or deoxyribose known in the industry, including, for example, 2'-O-methylribose, 2'-O-allylribose, 2'-fluororibose, or 2'-azidoribose; carbocyclic sugar analogs; α-anomeric or β-anomeric sugars; epimeric sugars such as arabinose, xylose, or lythose, pyranose, furanose, sedoheptulose; acyclic analogs; and baseless nucleoside analogs such as methylribonucleotides. One or more phosphodiester bonds can be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments in which the phosphate ester is replaced by P(O)S (“sulfate”), P(S)S (“disulfate”), (O)NR2 (“amino ester”), P(O)R, P(O)OR', CO, or CH2 (“methyl acetal”), wherein each R or R' is independently H or a substituted or unsubstituted alkyl group (1-20 Cs) (optionally containing an ether (-O-) bond), aryl, alkenyl, cycloalkyl, cycloalkenyl, or aromatic aldehyde. Not all links in a polynucleotide need to be identical. The foregoing description applies to all polynucleotides mentioned herein, including RNA and DNA.

[0039] In some embodiments, the antigen-binding domain is a recombinant antigen receptor. As used herein, the term “recombinant antigen receptor” broadly refers to a non-naturally occurring surface receptor that includes an extracellular antigen-binding domain or an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain. In some embodiments, the recombinant antigen receptor is a chimeric antigen receptor (CAR). Chimeric antigen receptors (CARs) are well known in the field. CARs are fusion proteins that contain an antigen recognition portion and a transmembrane region.Domains and T-cell activation domains (see, for example, Eshhar et al., Proc. Natl. Acad. Sci. USA, 90(2): 720-724 (1993)).

[0040] As used herein, the terms “extracellular ligand-binding domain” or “extracellular antigen-binding domain” refer to a polypeptide capable of binding a ligand or antigen or capable of interacting with cell surface molecules such as ligands or surface antigens. For example, extracellular ligand-binding or antigen-binding domains may be selected to recognize ligands used as cell surface markers (e.g., tumor-specific antigens) on target cells associated with a specific disease state. In some embodiments, the antigen-binding domain comprises an antibody or an antigen-binding fragment or antigen-binding portion of an antibody. In some embodiments, the antigen-binding domain comprises Fv or scFv, Fab or scFab, F(ab')2 or scF(ab')2, Fd, a monobody, an affibody, a camelid antibody, a VHH antibody, a single-domain antibody, or a darpin. In some embodiments, the ligand-binding domain comprises a partner of a binding pair, such as a ligand that binds to a surface receptor, or an extracellular domain of a surface receptor that binds to a ligand.

[0041] The term "intracellular signal transduction domain" refers to a portion of a protein that transduces effector signals and directs the cell to perform specialized functions.

[0042] References to "about" a value or parameter herein include (and describe) embodiments involving addition or subtraction of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of that value or parameter itself. For example, a reference to "about X" includes the description of "X". Numerical ranges include numbers that define the range.

[0043] It should be understood that wherever embodiments are described herein using the language “comprising”, similar embodiments are also provided for other aspects described using the terms “composed of” and / or “substantially composed of”. Specification 7 / 84 pages 10 CN 121532650 A

[0044] An “antigen-binding protein” comprises one or more antigen-binding domains. As used herein, “antigen-binding domain” means any polypeptide that binds a specified target antigen. In some embodiments, the antigen-binding domain binds to antigens on tumor cells. In some embodiments, the antigen-binding domain binds to antigens on cells involved in hyperproliferative diseases or to viral or bacterial antigens.

[0045] Antigen-binding domains include, but are not limited to, antibody-binding regions as immune functional fragments. An “immune functional fragment” (or “fraction”) of the term antigen-binding domain is an antigen-binding domain comprising a portion of an antibody (regardless of how that portion is obtained or synthesized) that lacks at least some amino acids present in the full-length chain, but is still capable ofSpecific binding to target antigens. Such fragments are biologically active because they bind to target antigens and can compete with other antigen-binding domains (including intact antibodies) for binding to a given epitope.

[0046] Immunofunctional immunoglobulin fragments include, but are not limited to, scFv fragments, Fab fragments (Fab′, F(ab′)2, etc.), one or more complementarity-determining regions (“CDRs”), biantibodies (heavy chain variable domains on the same polypeptide as light chain variable domains, linked via short peptide linkers that are too short to allow pairing between two domains on the same chain), domain antibodies, bivalent antigen-binding domains (containing two antigen-binding sites), multispecific antigen-binding domains, and single-chain antibodies. These fragments can be derived from any mammalian source, including but not limited to humans, mice, rats, camels, or rabbits. As those skilled in the art will understand, antigen-binding domains may include non-protein components.

[0047] Variable regions typically exhibit the same overall structure as relatively conserved frame regions (FRs) linked by three hypervariable regions (CDRs). The CDRs from the two strands of each pair are typically aligned by the frame region, thereby enabling them to bind to specific epitopes. From the N-terminus to the C-terminus, both the light and heavy chain variable regions typically contain domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. Conventionally, the CDR regions in the heavy chain are typically referred to as HC CDR1, CDR2, and CDR3. The CDR regions in the light chain are typically referred to as LC CDR1, CDR2, and CDR3.

[0048] In some embodiments, the antigen-binding domain comprises one or more complementary binding regions (CDRs) present in the full-length light or heavy chain of the antibody, and in some embodiments comprises a single heavy chain and / or a light chain or a portion thereof. These fragments can be generated using recombinant DNA technology, or can be generated by enzymatic or chemical cleavage of the antigen-binding domain, including the complete antibody.

[0049] In some embodiments, the antigen-binding domain is an antibody or a fragment thereof, including one or more of its complementarity-determining regions (CDRs). In some embodiments, the antigen-binding domain is a single-chain variable fragment (scFv) comprising light chain CDRs: CDR1, CDR2, and CDR3, and heavy chain CDRs: CDR1, CDR2, and CDR3.

[0050] The assignment of amino acids to each of the framework, CDRs, and variable domains generally conforms to the following numbering scheme: Kabat numbering (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, NIH Publication 91-3242, Bethesda Md. 1991); Chothia numbering (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, NIH Publication 91-3242, Bethesda Md. 1991);For example, Chothia and Lesk, (1987), J Mol Biol 196: 901-917; Al-Lazikani et al., (1997) J Mol Biol 273: 927-948; Chothia et al., (1992) J Mol Biol 227: 799-817; Tramontano et al., (1990) J Mol Biol 215(1): 175-82; and U.S. Patent No. 7,709,226); contact number, AbM protocol (Antibody Modeling program, Oxford Molecular) or AHo system (Honneger and Pluckthun, J Mol Biol (2001) 309(3):657-70).

[0051] In some embodiments, the antigen-binding domain is a recombinant antigen receptor. As used herein, the term “recombinant antigen receptor” broadly refers to a non-naturally occurring surface receptor that includes an extracellular antigen-binding domain or an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain. In some embodiments, the recombinant antigen receptor is a chimeric antigen receptor (CAR). Chimeric antigen receptors (CARs) are well known in the art. A CAR is a fusion protein that includes an antigen recognition portion, a transmembrane domain, and a T-cell activation domain (see, for example, Eshhar et al., Proc. Natl. Acad. Sci. USA, 90(2): 720–724 (1993)).

[0052] In the case where aspects or embodiments of this disclosure are described in groups according to Markush group or other alternatives, this disclosure covers not only the entire group listed as a whole, but also each member of the group individually and all possible subgroups of the main group, as well as the main group that does not have one or more group members. This disclosure also contemplates the explicit exclusion of one or more members of any group in the disclosed and / or claimed embodiments.

[0053] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In case of conflict, the specification, including the definitions, shall prevail. Throughout this specification and claims, the word “comprise” or variations such as “comprises” or “comprising” shall be understood to imply inclusion of the said integer or group of integers, but not to exclude any other integer or group of integers. Unless the context otherwise requires, singular terms shall include plural terms, and plural terms shall include singular terms.

[0054] Exemplary methods and materials are described herein, but similar or equivalent methods and materials may also be used in practice or testing of this disclosure. Materials, methods, and examples are illustrative only and are not intended to be limiting.

[0055] Analysis of Cell Populations In one aspect, this disclosure provides methods, assays, systems, compositions, and kits for population detection (and / or quantification or counting) of one or more engineered immune cells expressing a bicistronic expressed polypeptide from engineered immune cells (such as CAR T cells). In one embodiment, one or more engineered immune cells comprise a polynucleotide sequence encoding a bicistronic expressed polypeptide (or a vector comprising said polynucleotide sequence). In another embodiment, the polynucleotide sequence (or a vector comprising said polynucleotide sequence) further encodes a linker peptide and additional polypeptides. Typically, the bicistronic expressed polypeptide, linker peptide, and additional polypeptides (such as CAR polypeptides) are expressed in engineered immune cells and can be detected according to the methods described herein. In one embodiment, the methods described herein include the step of contacting engineered immune cells (e.g., CAR T cells) with an exogenous agent. In other embodiments, the methods further include detecting the linker peptide after the contact step. In another embodiment, the detection of the linker peptide indicates the presence of a bicistronic expressed polypeptide in the engineered immune cells.

[0056] The engineered cells may be engineered immune cells (e.g., CAR-T cells). Detection of bicistronic expressed polypeptides can provide important information about the engineered immune cell population before or after formulating an engineered immune cell population into a CAR T cell drug product and / or before administering the engineered immune cell population as part of a CAR T cell drug product to a subject. Additionally, detection of bicistronic expressed polypeptides in engineered immune cells during and / or after the manufacturing process can provide valuable information about the cells. For example, the disclosed method allows for the detection of bicistronic expressed polypeptides during and / or after the manufacturing process.

[0057] In another aspect, this disclosure relates to the analysis of different engineered immune cell populations. In one embodiment, the analysis includes screening methods for detecting engineered immune cells expressing bicistronic expressed polypeptides from an engineered immune cell population and / or for quantifying the number of said engineered immune cells. As discussed herein, methods for understanding the expression levels of bicistronic expressed peptides in engineered immune cell populations are valuable during engineered cell manufacturing processes. These methods are desirable not only for clarifying the presence of bicistronic expressed peptides in one or more cells within an engineered immune cell population, but also for accurately and precisely expressing bicistronic peptides within a given immune cell population.Quantifying the expression frequency of the bicistronic expressed peptide in the population is also important. Screening methods include, but are not limited to, screening engineered immune cells during or after the manufacturing process. In one embodiment, the screening includes contacting an engineered immune cell population (page 9 / 84, CN 121532650 A) with an exogenous agent, followed by a step of detecting the bicistronic expressed peptide.

[0058] In one aspect, the screening method is a quantitative and / or qualitative method. For the screening methods described herein, the detection of the bicistronic expressed peptide in engineered immune cells from an engineered immune cell population can be performed using various methods, including but not limited to flow cytometry, fluorescence-activated cell sorting (FACS) flow cytometry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunofiltration assay (ELIFA), Western blotting, immunofluorescence assay, immunochemical assay (IHC), Western blot analysis, and immunoprecipitation, molecular binding assay.

[0059] Detection using flow cytometry. Instruments for particle analysis (e.g., flow cytometers and scanning cytometers) allow the characterization of individual particles or cells (e.g., a single engineered immune cell from an engineered population of immune cells) using optical parameters such as light scattering and fluorescence. For example, a flow cytometer allows an aqueous suspension containing individual particles (e.g., beads containing the target analyte) or cells to pass through a detection zone that exposes the suspension to an excitation light source (such as one or more lasers), enabling the user to measure the light scattering and fluorescence properties of the particles or cells. Labeling particles or cells with one or more fluorescent dyes can facilitate detection. Multiple different particles or cells can be subjected to flow cytometry for simultaneous detection by labeling them with spectrally distinguishable dyes. In other embodiments, multiple photodetectors can be used to measure different scattering parameters and / or different spectrally distinguishable dyes. For example, one or more detectors can be configured to measure one or more sets of scattering parameters, and one or more additional detectors can be configured to measure one or more different dyes, thereby allowing the generation of data containing signals for each light scattering parameter and each fluorescence emission.

[0060] Commonly measured flow cytometry parameters include, but are not limited to: (i) excitation light scattered by particles or cells in a predominantly forward direction, or forward scattering (FSC); (ii) excitation light scattered by particles or cells in a predominantly transverse direction, or side scattering (SSC); and (ii) light emission from fluorescent molecules in one or more channels (frequency ranges) of the spectrum or from fluorescent dyes primarily detected in that channel. In one embodiment, FSC, SSC, and fluorescence can be used to measure these parameters.Emissions are used to identify different cell types from engineered immune cell populations, wherein the FSC, SSC, and fluorescence emission are obtained by labeling various cell surface proteins on the cells with dye-labeled antibodies.

[0061] Data obtained from the analysis of particles or cells (e.g., single engineered immune cells from engineered immune cell populations) by multicolor flow cytometry is multidimensional, wherein each cell corresponds to a point in a multidimensional space defined by the measured parameters. Populations of cells or particles are identified as clusters of points in the data space. Identification of clusters and thus of populations can be performed manually by drawing gates around the populations displayed in one or more 2D plots of the data (referred to as “scatter plots” or “dot plots”). Alternatively, clusters can be identified, and the gates defining the population boundaries can be determined automatically. Flow cytometry is an important tool for analyzing and / or separating particles or cells (e.g., individual engineered immune cells from engineered immune cell populations) and cell analytes or components thereof. Therefore, flow cytometry can be used in the analysis and / or separation of engineered immune cells. In one embodiment, this disclosure provides a method for linearly separating donor cells from an engineered immune cell population using a fluid stream, such that they pass individually through a detection device. Single cells from the engineered immune cell population can be distinguished from other cells based on their position in the fluid stream and the presence of detectable markers. Thus, flow cytometry can be used to detect one or more bicistronic expressed peptides (as described herein) and / or generate bicistronic expressed peptide expression profiles of engineered immune cell populations. Such profiles may include the percentage of cells expressing bicistronic expressed peptides (as further described herein) in the total cell population being analyzed.

[0062] In another aspect, this disclosure provides a method for detecting engineered immune cells expressing bicistronic expressed peptides from an engineered immune cell population by detecting the level of bicistronic expressed peptides. In one embodiment, page 10 / 84 of CN 121532650 A, the detected level indicates that some engineered immune cells express bicistronic expressed peptides. On the other hand, the level of bicistronic expressed peptide detected indicates the number of engineered immune cells expressing the bicistronic expressed peptide in the engineered immune cell population being analyzed.

[0063] In some embodiments, the method provides a quantitative measurement of engineered immune cells from an engineered immune cell population that do not express the bicistronic expressed peptide. Flow cytometry can be used to quantify cells within a cell population that express or do not express the bicistronic expressed peptide, and / or to quantify cells of a specific cell type.

[0064] As described herein, flow cytometry is a technique that primarily uses optical means to employ certain labeling agents (as further described herein)(Description) Methods for quantifying the components or structural characteristics of cells. Because different cell types can be distinguished by quantifying structural characteristics, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture. Flow cytometry analysis involves two main steps: 1) labeling the selected cell type with one or more detectable markers or reagents, and 2) determining the number of labeled cells relative to the total number of cells in the population. In some embodiments, the method of labeling cell types includes binding a labeled antibody to a marker expressed by a specific cell type. The antibody may be directly labeled with a fluorescent compound or indirectly labeled using, for example, a second antibody that recognizes a first antibody and is fluorescently labeled.

[0065] In another aspect, this disclosure utilizes flow cytometry to provide a method for generating an expression profile of a bicistronic expressed peptide expressed in an engineered immune cell population based on the percentage of cells that detect bicistronic expressed peptides. In one embodiment, the method includes providing an engineered immune cell population suspected of containing a bicistronic expressed peptide. In another embodiment, the method further includes contacting the engineered immune cell population with an exogenous pharmaceutical agent. In another embodiment, the method includes detecting the level of a bicistronic expressed peptide in a population of engineered immune cells after a contact step, wherein the detected level of the bicistronic expressed peptide indicates that a certain percentage of the engineered immune cell population expresses the bicistronic expressed peptide. In other embodiments, the method further includes detecting the level of additional peptides in a population of engineered immune cells after a contact step, wherein the detected level of the additional peptides indicates that a certain percentage of the engineered immune cell population expresses the additional peptide. In some embodiments, the method includes detecting the levels of both the bicistronic expressed peptide and additional peptides, wherein the detected levels indicate the percentage expression of both the bicistronic expressed peptide and the additional peptide in the engineered immune cell population.

[0066] In one embodiment, the quantitative screening method is flow cytometry. In one aspect, the methods, assays, systems, compositions, and kits described herein can be used at different stages of manufacturing an engineered cell population. As shown in FIG5, the immune cell population can undergo manufacturing steps 10-15, followed by screening of the population for the expression of the bicistronic expressed peptide at point 16. The screening results at position 16 inform the decision on whether to continue formulating cell therapy products (e.g., CAR T-cell therapy products) using the engineered immune cell population. If a bicistronic expressed peptide is detected at position 18, the engineered immune cell population is considered to have failed the screening assay. If a bicistronic expressed peptide is detected at position 17, the bicistronic expressed peptide is considered to have passed the screening assay and can proceed forward in the cell therapy product manufacturing process.

[0067] In one embodiment, the cell therapy product batch containing engineered immune cells passing through point 17 may be derived from a subject who will ultimately receive the engineered immune cell population. For example, the engineered immune cells may comprise autologous immune cells obtained from a subject who will ultimately receive engineered immune cells (e.g., CAR T cells) derived from autologous immune cells. In other embodiments, the engineered immune cells passing through point 17 may be derived from a donor who is a different individual from the subject who will receive the engineered cell population. For example, the engineered immune cells may comprise allogeneic immune cells obtained from a healthy donor who is a different individual from the subject who will receive engineered immune cells (e.g., CAR T cells) derived from allogeneic immune cells. Specification 11 / 84 pages 14 CN 121532650 A

[0068] In one embodiment, according to the workflow in FIG5, screening 16 may be performed after 13 or after 14, in addition to screening after 15 or as an alternative to screening after 15. Alternatively, screening 16 can be delayed until after screening 19, where the engineered immune cells, as a CAR T-cell therapy product, complete the manufacturing process final stage with cryopreservation 19. The cryopreserved product can be completely thawed, and then a sample of the product can be screened 16 to determine whether the test passes or fails.

[0069] Bicistronic expressed peptides In one aspect, this disclosure relates to engineered immune cells and populations comprising said engineered immune cells, and methods for detecting peptides expressed by said cells and populations. In one embodiment, the peptide expressed by said cells is a bicistronic expressed peptide. In another embodiment, one or more bicistronic expressed peptides are expressed from a polynucleotide or a vector comprising said polynucleotide, said polynucleotide comprising several different elements. As described herein, the polynucleotide comprises a first nucleic acid sequence encoding a first peptide and a second nucleic acid sequence encoding a second peptide, wherein said first and second nucleic acid sequences are separated by a third nucleic acid sequence encoding a linker peptide. In one embodiment, the third nucleic acid sequence encodes a series of amino acids, wherein the first amino acid is attached to the C-terminus of the bicistronic expressed peptide during translation. In another embodiment, the second amino acid translated after the translation of the first amino acid is the first N-terminal amino acid of the second peptide. In another embodiment, the first and second amino acids are characterized by the absence of a peptide bond between them. In one embodiment, the first polypeptide contains the first amino acid at its C-terminus. In another embodiment, the second polypeptide contains the second amino acid at its N-terminus. In one embodiment, the first amino acid is glycine and / or the second amino acid is proline.

[0070] In other embodiments, the method described herein relates to detecting a first polypeptide as a bicistronic expressed polypeptide. In another embodiment, the second polypeptide is a CAR. In some embodiments, the detected first polypeptide (i.e., the bicistronic expressed polypeptide) is a polypeptide different from the second polypeptide (i.e., the CAR). The first polypeptide (i.e., the bicistronic expressed polypeptide) can be any polypeptide, including but not limited to receptor polypeptides, membrane polypeptides, cytoplasmic polypeptides, and secretory polypeptides.

[0071] In one embodiment, the first polypeptide is a membrane polypeptide containing an intracellular domain. In one embodiment, the intracellular domain is an intracellular signal transduction domain. In another embodiment, the intracellular signal transduction domain is a cytokine signal transduction domain.

[0072] In one embodiment, the first polypeptide is a chimeric cytokine receptor (CCR). In another embodiment, the CCR is an inducible CCR. Typically, an inducible CCR is a receptor that responds to ligands (such as small molecules (e.g., AP1903)) or proteins (e.g., Epo, Tpo, or PD-L1)). Inducible CCRs can be expressed in engineered immune cells (e.g., CAR T cells) to improve cytokine-induced cytokine receptor signaling (see US2019-0292533A1, which is incorporated herein by reference in its entirety). In one aspect, the present invention provides an inducible chimeric cytokine receptor comprising: a dimerizing domain; a tyrosine kinase activation domain; and a tyrosine effector domain. In some embodiments, the tyrosine kinase activation domain comprises a protein- or protein-derived Janus kinase (JAK) binding domain. In some embodiments of these embodiments, the tyrosine kinase activation domain further comprises a transmembrane domain. In some embodiments, the tyrosine kinase activation domain comprises a receptor tyrosine kinase (RTK) or a receptor tyrosine kinase (RTK)-derived tyrosine kinase domain. In some embodiments of these embodiments, the tyrosine kinase activation domain further comprises a transmembrane domain.

[0073] In another embodiment, the CCR is a CCR lacking an extracellular domain. In yet another embodiment, the CCR is a constitutively active chimeric cytokine receptor (CACCR). The presence of constitutively active, tunable chimeric cytokine receptors allows for immune enhancement of signal 3 to meet the need for immune enhancement (see US2020-0291090A1, which is incorporated herein by reference in its entirety). Typically, the CACCR of this disclosure consists of two monomers, each comprising: (a) a transmembrane domain; (b) a JAK-binding domain; and (c) a recruitment domain, wherein the monomer is constitutively dimerized. In some...In embodiments, the CACCR of this disclosure does not contain an extracellular ligand-binding domain. In some embodiments, the monomers are identical, resulting in a constitutively active homodimer. In some embodiments, the monomers are different, resulting in a constitutively active heterodimer, which may be desirable in certain situations. The monomers of the CACCR of this disclosure are capable of spontaneous dimerization and can activate signal transduction in the absence of any exogenous stimulus or ligand (ligand-independent dimerization).

[0074] Exemplary amino acid sequences that can be used in the CACCR are provided in Table 1A.

[0075] Table 1A: Exemplary transmembrane domain amino acid sequences

[0076] Exemplary transmembrane and JAK binding sequences that can be used in the CACCR provided herein are shown in Table 1B.

[0077] Table 1B: Exemplary transmembrane + JAK2 binding domain sequences Specification 13 / 84 pages 16 CN 121532650 A Specification 14 / 84 pages 17 CN 121532650 A

[0078] Table 1C provides exemplary amino acid sequences of the recruitment domain of the CACCR of this disclosure. In some embodiments, the CACCR of this disclosure includes a recruitment domain comprising an amino acid sequence selected from one or more receptor sequences in Table 1C. In some embodiments, the CACCR of this disclosure includes a recruitment domain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to any one of the sequences in Table 1C.

[0079] Table 1C: Recruitment Domain (Cytotail) Sequence Specification 15 / 84 pages 18 CN 121532650 A Specification 16 / 84 pages 19 CN 121532650 A Specification 17 / 84 pages 20 CN 121532650 A

[0080] Table 1D shows exemplary CACCR sequences of this disclosure (e.g., full-length CACCR sequences or components thereof). CACCR may be expressed together with a signal sequence (e.g., CD8SS of the sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 127)).

[0081] Table 1D – Constitutive Active Chimeric Cytokine Receptor (CACCR) Sequence Specification 18 / 84 Page 21 CN 121532650 A Specification 19 / 84 Page 22 CN 121532650 A Specification 20 / 84 Page 23 CN 121532650 A Specification 21 / 84 Page 24 CN 121532650 A Specification 22 / 84 Page 25 CN 121532650 A SpecificationPages 23 / 84, 26 CN 121532650 A Specification Pages 24 / 84, 27 CN 121532650 A

[0082] *Underlined LE and SR are exemplary optional linkers that can be inserted between the two domains.

[0083] In another embodiment, the CCR is an inducible PD-1 CCR that is active upon binding to a PD-1 ligand or upon activation with an anti-PD-1 antibody (see US2020-0276238A1, which is incorporated herein by reference in its entirety). Constitutively active PD-1 chimeric cytokine receptors are also provided herein. Engineered immune cells (e.g., CAR T cells) expressing the PD-1 CCRs of this disclosure are provided herein. In one embodiment, the inducible PD-1 CCRs of this disclosure activate signal transduction upon, for example, binding to a PD-1 ligand (e.g., PD-L1, PD-L2) or a PD-1 antibody. These receptors activate signal transduction upon monomeric clustering and / or dimerization of the receptor. In some embodiments, the monomer of the PD-1 CCR of this disclosure comprises: (a) a PD-1 extracellular domain; (b) a transmembrane domain; (c) a Janus kinase (JAK) binding domain; and (d) a STAT recruitment domain (e.g., a cytoplasmic domain derived from a receptor; e.g., from a cytokine receptor). The recruitment domain may be a STAT recruitment domain, an AP1 recruitment domain, a Myc / Max recruitment domain, or an NFkB recruitment domain. The PD-1 chimeric cytokine receptor can bind to a PD-1 ligand and / or be clustered and activated with an anti-PD-1 antibody. PD-1 chimeric cytokine receptors activate signal transduction, for example, upon binding to PD-L1 ligands, PD-L2 ligands, and / or PD-1 antibodies.

[0084] Regardless of PD-1 ligand availability, the constitutively active PD-1 CCR of this disclosure is active, but its activity may be increased in the presence of a PD-ligand. In some embodiments, the monomer of the constitutively active PD-1 CCR of this disclosure comprises: (a) a PD-1 extracellular domain; (b) a transmembrane domain; (c) a Janus kinase (JAK) binding domain; and (d) a STAT recruitment domain (e.g., a cytoplasmic domain derived from a receptor; e.g., derived from a cytokine receptor). In some embodiments, the monomer of the constitutively active PD-1 CCR of this disclosure comprises: (a) a PD-1 extracellular domain; (b) a transmembrane domain; (c)Janus kinase (JAK) binding domain; and (d) recruitment domain (e.g., a cytoplasmic domain from the receptor; e.g., from a cytokine receptor). The recruitment domain may be a STAT recruitment domain, an AP1 recruitment domain, a Myc / Max recruitment domain; or an NFkB recruitment domain. In some embodiments, constitutively active PD-1 CCRs may bind to PD-1 ligands or anti-PD-1 antibodies and / or cluster, and receptor activity may be further increased by binding to PD-1 ligands or anti-PD-1 antibodies.

[0085] Table 1E shows exemplary PD1 amino acid extracellular domain sequences of the present disclosure. It should be noted that the expression and extracellular location of exemplary PD1 amino acid sequences can be obtained by using signal sequences. In an exemplary embodiment, the CD8 signal sequence (CD8SS) MALPVTALLLPLALLLHAARP (SEQ ID NO: 127) is utilized.

[0086] Table 1E: Exemplary Extracellular Domain Sequence Specification 26 / 84 pages 29 CN 121532650 A

[0087] In some embodiments, the PD-1 extracellular domain is dominant-negative. Table 1F shows exemplary PD-1 dominant-negative (DN) sequences of this disclosure. The DN sequences in Table 1E can be expressed with the aid of a signal sequence (e.g., the CD8SS signal sequence of SEQ ID NO: 127).

[0088] Table 1F: PD1 Dominant-Negative (DN) Sequences:

[0089] Table 1G shows exemplary transmembrane amino acid sequences coupled to intracellular JAK2 binding domain sequences for use in PD-1 CCR.

[0090] Table 1G: Exemplary transmembrane + JAK2 binding domain sequence Specification 27 / 84 pages 30 CN 121532650 A Specification 28 / 84 pages 31 CN 121532650 A

[0091] In some embodiments, the PD-1 chimeric cytokine receptor of this disclosure comprises an amino acid sequence of a STAT recruitment domain, said amino acid sequence being at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to the amino acid sequence of any of the sequences shown in Table 1H.

[0092] Table 1H: Recruitment domain sequence (tail sequence) Specification 29 / 84 pages 32 CN 121532650 A Specification 30 / 84 pages 33 CN 121532650 A Specification 31 / 84 pages 34 CN 121532650 A

[0093] Table 1I shows exemplary PD-1 CCR sequences of this disclosure. The receptor may be expressed together with a signaling sequence (e.g., CD8SS of SEQ ID NO: 127).

[0094] Table 1I: Exemplary PD-1CCR sequence (assembled PD1 chimeric cytokine receptor) Instruction manual 32 / 84 pages 35 CN 121532650 A Instruction manual 33 / 84 pages 36 CN 121532650 A Instruction manual 34 / 84 pages 37 CN 121532650 A Instruction manual 35 / 84 pages 38 CN 121532650 A Instruction manual 36 / 84 pages 39 CN 121532650 A Instruction manual 37 / 84 pages 40 CN 121532650 A Instruction manual 38 / 84 pages 41 CN 121532650 A Instruction manual 39 / 84 pages 42 CN 121532650 A Instruction manual 40 / 84 pages 43 CN 121532650 A Instruction manual 41 / 84 pages 44 CN 121532650 A Instruction manual 42 / 84 pages 45 CN 121532650 A Instruction Manual 43 / 84 Pages 46 CN 121532650 A Instruction Manual 44 / 84 Pages 47 CN 121532650 A Instruction Manual 45 / 84 Pages 48 CN 121532650 A Instruction Manual 46 / 84 Pages 49 CN 121532650 A Instruction Manual 47 / 84 Pages 50 CN 121532650 A Instruction Manual 48 / 84 Pages 51 CN 121532650 A Instruction Manual 49 / 84 Pages 52 CN 121532650 A Instruction Manual 50 / 84 Pages 53 CN 121532650 A Instruction Manual 51 / 84 Pages 54 CN 121532650 A Instruction Manual 52 / 84 Pages 55 CN 121532650 A Instruction Manual 53 / 84 Pages 56 CN 121532650 A Specification 54 / 84 pages 57 CN 121532650 A

[0095] In another embodiment, the CCR is a CCR containing a TGF-β binding domain. In one embodiment, the CCR is an inducible CCR that is active upon conjugation to a TGF-β ligand (e.g., TGF-β1, TGF-β2, and / or TGF-β3) or activation with an anti-TGF-β receptor antibody (see US2021-0061881A1, which is incorporated herein by reference in its entirety). This document provides engineered immune cells (e.g., CAR T cells) expressing the TGF-β CCR of this disclosure. The CCR of this disclosure in TGF-βBinding of a ligand (e.g., TGF-β1, TGF-β2, and / or TGF-β3) or an anti-TGF-β receptor antibody activates signal transduction. These receptors activate signal transduction upon monomeric clustering and / or dimerization of the receptor. The chimeric cytokine receptor of this disclosure is a bifunctional chimeric cytokine receptor that can simultaneously neutralize the immunosuppressive effects of TGF-β ligands and mimic the transmission of immune-enhancing cytokine signaling. In some embodiments, the monomer of the chimeric cytokine receptor of this disclosure comprises: (a) a binding domain capable of binding a TGF-β ligand or an anti-TGF-β receptor antibody; (b) a transmembrane domain; (c) a Janus kinase (JAK) binding domain; and (d) a STAT recruitment domain (e.g., a cytoplasmic domain derived from the receptor; e.g., derived from the cytokine receptor). Each domain may be directly linked or linked via one or more peptide linkers. In some embodiments, the monomer of the chimeric cytokine receptor of this disclosure comprises: (a) a binding domain capable of binding to a TGF-β ligand or an anti-TGF-β receptor antibody; (b) a transmembrane domain; (c) a Janus kinase (JAK) binding domain; and (d) a recruitment domain (e.g., a cytoplasmic domain derived from the receptor; e.g., derived from the cytokine receptor). The recruitment domain may be a STAT recruitment domain, an AP1 recruitment domain, a Myc / Max recruitment domain; or an NFkB recruitment domain. In some embodiments, the chimeric cytokine receptor clusters and activates upon binding to a TGF-β ligand, and / or clusters and activates with an anti-TGF-β receptor antibody. The chimeric cytokine receptor activates signal transduction, for example, upon binding to a TGF-β ligand and / or a TGF-β receptor antibody. In some embodiments, the TGF-β receptor antibody is, but is not limited to, PF-03446962 or LY3022859. In some embodiments, the chimeric cytokine receptor constitutively clusters or dimers.

[0096] Linker peptides In one aspect, the in vitro methods described herein utilize linker peptides. In one embodiment, the linker peptide is part of a bicistronic expressed polypeptide. In other embodiments, engineered immune cells (e.g., CAR T cells) comprise a polynucleotide sequence encoding a bicistronic expressed polypeptide, a linker peptide, and additional polypeptides. Table 1J provides a list of exemplary linker peptides and their amino acid sequences. Specification 55 / 84 pages 58 CN 121532650 A

[0097] Table 1J – Linker peptides

[0098] In one embodiment, the amino acid sequence of the linker peptide comprises D-(V or I)-E-x-N-P-G-P, where x is any amino acid. After translation, the amino acid sequence attached to the C-terminus of the first polypeptide (i.e., the bicistronic expressed polypeptide) comprises D-(V or I)-E-x-N-P-G, where x is any amino acid.

[0099] This disclosure covers modifications of peptides, including bicistronic expressed peptides and CARs, and linker peptides comprising the sequences provided herein (e.g., Tables 1J and 2), including functionally equivalent bicistronic expressed peptides, CARs, or linker peptides with modifications that do not significantly affect their properties, as well as variants with enhanced or decreased activity. For example, the amino acid sequence of a linker peptide can be altered (e.g., with deletions, insertions, and / or substitutions) to obtain a linker peptide with desired properties. Modification of peptides and polypeptides is common practice in the art and therefore need not be described in detail herein. Examples of modified peptides or polypeptides include peptides or polypeptides having conserved substitutions of amino acid residues, deletions of one or more amino acids, or additions, which do not significantly and harmfully alter the functional activity of the linker peptide, the bicistronic expressed peptide comprising the linker peptide, and / or the CAR, or the modification enhances their functionality. Deletions may include deletions of one or more ends of the linker peptide.

[0100] Amino acid sequence insertions include amino-terminal fusions and / or carboxyl-terminal fusions ranging in length from one to several residues, as well as intra-sequence insertions of one or more amino acid residues.

[0101] Substitution variants remove at least one amino acid residue from polypeptides and peptides and insert different residues at their positions. Conservative substitutions are shown under the heading "Conservative Substitutions" in Table 2. If such substitutions result in a change in biological activity, more substantial changes (named "Exemplary Substitutions" in Table 2, or further described below with respect to amino acid categories) can be introduced and products screened.

[0102] Table 2: Amino Acid Substitution Specification 56 / 84 pages 59 CN 121532650 A

[0103] Immunocell engineered immune cells are obtained from donor cells. Engineered cells derived from donor cells suitable for use with the methods and / or reagents described herein include immune cells.

[0104] Donor cells (e.g., immune cells) for use in the methods described herein can be obtained from a subject prior to in vitro manipulation or genetic modification (e.g., as described herein). Donor cells can be obtained from a variety of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, stem cell-derived or iPSC-derived immune cells, tissue from sites of infection, ascites, pleural effusion, spleen tissue, and tumors. In some embodiments, any number of T cell lines available and known to those skilled in the art can be used. In some embodiments, donor cells can be derived from healthy donors, from patients diagnosed with cancer, from patients diagnosed with autoimmune disorders, or from patients diagnosed with infections. In some embodiments, donor cells can be part of a mixed population of cells exhibiting different phenotypic characteristics.

[0105] In some embodiments, the immune cells are obtained from a subject who will ultimately receive engineered immune cells.Autologous immune cells. In some embodiments, the immune cells are allogeneic immune cells obtained from a donor, which is an individual different from the subject who will receive the engineered immune cells.

[0106] In some embodiments, the immune cells include T cells. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, stem cell-derived or iPSC-derived T cells, tissue from sites of infection, ascites, pleural effusion, spleen tissue, and tumors. In some embodiments, T cells can be obtained from a volume of blood collected from the subject using any number of techniques known to those skilled in the art (such as FICOLL™ isolation).

[0107] Donor cells can be obtained from an individual's circulating blood via apheresis. Apheresis products typically contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In some embodiments, cells collected via apheresis may be washed to remove the plasma fraction and placed in a suitable buffer or medium for subsequent processing.

[0108] Donor PBMCs may be used directly for genetic modification with immune cells (such as CARs or TCRs) as described herein. In some embodiments, T lymphocytes may be further isolated after PBMC isolation, before or after genetic modification and / or amplification, and both cytotoxic and helper T lymphocytes may be sorted into naive, memory, and effector T cell subsets.

[0109] In some embodiments, T cells are isolated from PBMCs by lysing erythrocytes and depleting monocytes (e.g., using centrifugation via a PERCOLL™ gradient). Specific subsets of T cells (such as CCR7+, CD95+, CD122, CD27+, CD69+, CD127+, CD28+, CD3+, CD4+, CD8+, CD25+, CD62L+, CD45RA+, and CD45RO+ T cells) can be further isolated using positive or negative selection techniques known in the art. For example, enriching a T cell population by negative selection can be accomplished using a combination of antibodies against surface markers specific to the negatively selected cells. One method used herein is cell sorting and / or selection or flow cytometry via negative magnetic immunoadsorption, using a mixture of monoclonal antibodies against cell surface markers present on the negatively selected cells. For example, to enrich CD4+ cells by negative selection, the monoclonal antibody mixture typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. Flow cytometry and cell sorting can also be used to isolate a target cell population for use in this disclosure.

[0110] In some embodiments, a population of donor cells (e.g., immune cells, such as T cells) is enriched with CD4+ cells.

[0111] In some embodiments, a population of donor cells (e.g., immune cells, such as T cells) is enriched with CD8+ cells.

[0112] In some embodiments, CD8+ cells are further sorted into naive, central memory, and effector cells by identifying cell surface antigens associated with each of these cell types. In some embodiments, the expression of phenotypic markers for naive T cells includes CD45RA+, CD95-, IL2Rβ-, CCR7+, and CD62L+. In some embodiments, the expression of phenotypic markers for stem cell memory T cells includes CD45RA+, CD95+, IL2Rβ+, CCR7+, and CD62L+. In some embodiments, the expression of phenotypic markers for central memory T cells includes CD45RO+, CD95+, IL2Rβ+, CCR7+, and CD62L+. In some embodiments, the expression of phenotypic markers of effector memory T cells includes CD45RO+, CD95+, IL2Rβ+, CCR7-, and CD62L-. In some embodiments, the expression of phenotypic markers of T effector cells includes CD45RA+, CD95+, IL2Rβ+, CCR7-, and CD62L-. Therefore, by identifying cell populations with cell surface antigens, CD4+ and / or CD8+ T helper cells can be sorted into naive, stem cell memory, central memory, effector memory, and T effector cells.

[0113] It will be understood that donor PBMCs may also include other cytotoxic lymphocytes, such as NK cells or NKT cells. Expression vectors carrying the coding sequence of chimeric receptors as disclosed herein can be introduced into populations of human donor T cells, NK cells, or NKT cells. CAR-expressing T cells are cryopreserved using standard procedures for storage and / or preparation for use in human subjects. In one embodiment, the in vitro transduction, culture, and / or expansion of T cells are performed in the absence of products of non-human animal origin (such as fetal calf serum and fetal bovine serum). In various embodiments, the cryopreservation medium may include, for example, CryoStor® CS2, CS5, or CS10, or another medium containing DMSO or a medium not containing DMSO.

[0114] Engineered Immune Cells This document provides engineered immune cells (e.g., CAR-T cells) expressing bicistronic peptides and other peptides (e.g., CARs) of the present disclosure, which are obtained from donor cells as described herein. Specification 58 / 84 pages 61 CN 121532650 A

[0115] In some embodiments, the engineered immune cells comprise a polynucleotide sequence encoding a bicistronic expression polypeptide, a linker peptide, and another polypeptide (e.g., a CAR). In one embodiment, the CAR comprises one or more extracellular antigen-binding domains. In some embodiments, the engineered immune cells comprise a population of CARs, each CAR comprising a different extracellular antigen-binding domain. In some embodiments, the immune cells comprise a population of CARs, each CAR comprising the same extracellular antigen-binding domain.

[0116] The engineered immune cells may be allogeneic or autologous.

[0117] In some embodiments, the engineered immune cells are T cells (e.g., inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes, helper T lymphocytes, tumor-infiltrating lymphocytes (TILs)), NK cells, NK-T cells, TCR-expressing cells, dendritic cells, cytotoxic dendritic cells, mast cells, or B cells.

[0118] In some embodiments, the engineered immune cells may be obtained from or derived from a group consisting of CD4+ T lymphocytes and CD8+ T lymphocytes. In some exemplary embodiments, the engineered immune cells are T cells. In some exemplary embodiments, the engineered immune cells are αβ T cells. In some exemplary embodiments, the engineered immune cells are γδ T cells. In some exemplary embodiments, the engineered immune cells are macrophages.

[0119] In some embodiments, the engineered immune cells may be derived from, for example, but not limited to, stem cells. Stem cells may be adult stem cells, non-human embryonic stem cells (more specifically, non-human stem cells), umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells (iPSCs), pluripotent stem cells, or hematopoietic stem cells. Stem cells may be CD34+ or CD34-.

[0120] In some embodiments, the donor cells are obtained or prepared from peripheral blood. In some embodiments, the donor cells are obtained or prepared from peripheral blood mononuclear cells (PBMCs). In some embodiments, the donor cells are obtained or prepared from bone marrow. In some embodiments, the donor cells are obtained or prepared from umbilical cord blood. In some embodiments, the donor cells are human cells. In some embodiments, transfection or transduction will be performed using a nucleic acid vector and a method selected from the group consisting of: electroporation, acoustic pore effect, gene gun method (e.g., gene gun), transfection, lipid transfection, polymer transfection, nanoparticles, viral transduction or viral transfection (e.g., retrovirus, lentivirus, AAV), or polyplex. In some embodiments, the donor cells are T cells that have been reprogrammed from non-T cells. In some embodiments, the donor cells are T cells that have been reprogrammed from T cells.

[0121] Detection agents (including antibodies and fragments thereof)In embodiments, the disclosed methods for detecting bicistronic expressed polypeptides in engineered immune cells include using antibodies or antigen-binding agents (e.g., containing an antigen-binding domain or containing an antibody or a fragment thereof). As discussed below, in various embodiments, engineered immune cells derived from donor cell populations may also contain a binding agent.

[0122] As used herein, the term "antibody" refers to a polypeptide containing a canonical immunoglobulin sequence element sufficient to confer specific binding to a particular target antigen. As is known in the art, a complete antibody produced in nature is a tetramer of approximately 150 kD, consisting of two identical heavy chain polypeptides (each about 50 kD) and two identical light chain polypeptides (each about 25 kD), said heavy chain polypeptides and light chain polypeptides associating with each other in a structure generally referred to as a "Y-shape". Each heavy chain consists of at least four domains (each approximately 110 amino acids long): an amino-terminal variable (VH) domain (located at the top of the Y-shape), followed by three constant domains: CHI, CH2, and a carboxyl-terminal CH3 domain (located at the base of the Y-shaped stem). A short region called a “switch” connects the variable and constant regions of the heavy chain. A “hinge” connects the CH2 and CH3 domains to the rest of the antibody. In a complete antibody, two disulfide bonds in this hinge region link the two heavy chain polypeptides together. Each light chain consists of two domains: an amino-terminal variable (VL) domain, followed by a carboxyl-terminal constant (CL) domain. Those skilled in the art are well familiar with antibody structures and sequence elements, recognize the “variable” and “constant” regions in the provided sequence, and understand that there may be some flexibility in the definition of a “boundary” between such domains, allowing different presentations of the same antibody chain sequence to indicate, for example, that the position of this boundary is shifted by one or several residues relative to different presentations of the same antibody chain sequence.

[0123] A complete antibody tetramer consists of two heavy-chain-light-chain dimers, wherein the heavy and light chains are linked to each other by a single disulfide bond; two other disulfide bonds link the heavy-chain hinge regions to each other, causing the dimers to link together and form a tetramer. Naturally occurring antibodies are also glycosylated, typically at the CH2 domain. Each domain in a natural antibody has a structure characterized by “immunoglobulin folding,” which is formed by two β-sheets (e.g., 3-, 4-, or 5-strand sheets) stacked on top of each other in a compressed antiparallel β-barrel. Each variable domain contains three hypervariable loops called “complement-determining regions” (CDR1, CDR2, and CDR3) and four partially invariant “framework” regions (FR1, FR2, FR3, and FR4). During natural antibody folding, the FR regions form β-sheets that provide a structural framework for the domain, and the CDR loop regions from both the heavy and light chains are in three dimensions.They come together in space, causing them to generate a single hypervariable antigen-binding site at the apex of the Y structure. The Fc region of naturally occurring antibodies binds to elements of the complement system and also to receptors on effector cells, including, for example, effector cells mediating cytotoxicity. As is known in the art, the affinity and / or other binding properties of the Fc region to the Fc receptor can be modulated by glycosylation or other modifications. In some embodiments, antibodies generated and / or utilized according to the invention include glycosylated Fc domains, including modified or engineered such glycosylated Fc domains.

[0124] For the purposes of this disclosure, in some embodiments, any polypeptide or polypeptide complex containing a sufficient immunoglobulin domain sequence as found in natural antibodies may be referred to as and / or used as an “antibody,” whether such polypeptide is naturally generated (e.g., generated by an organism reacting with an antigen) or produced by recombinant engineering, chemical synthesis, or other artificial systems or methods. In some embodiments, the antibody is polyclonal; in some embodiments, the antibody is monoclonal. In some embodiments, the antibody has a constant region sequence characteristic of mouse, rabbit, primate, or human antibodies. In some implementations, the antibody sequence element is humanized, primate-derived, chimeric, etc., as known in the art.

[0125] Furthermore, as used herein, the term "antibody" may refer to any construct or form known in the art or developed for utilizing the structural and functional features of antibodies in alternative presentations. For example, in some embodiments, the antibodies used in the methods of this disclosure are selected from, but not limited to, the following forms: intact IgA, IgG, IgE, or IgM antibodies; bispecific or multispecific antibodies (e.g., Zybodies®, etc.); antibody fragments, such as Fab fragments, F(ab)2 fragments, Fd fragments, and isolated CDRs or collections thereof; single-chain variable fragments (scFV); peptide-Fc fusions; single-domain antibodies (e.g., shark single-domain antibodies, such as IgNAR or fragments thereof); camel antibodies (also referred to herein as nanobodies or VHH); shark antibodies, masking antibodies (e.g., Probodies®); small modular immunopharmaceuticals (SMIP™); single-chain or tandem biantibodies (TandAb®); VHH; Anticalins®; Nanobodies® microantibodies; BiTE®; ankyrin repeats or DARPINs®; Avimers®; DART; TCR-like antibodies; Adnectins® ; Affilins ® ; Trans‑bodies ® ; Affibodies ® ; TrimerX ® ; MicroProtein; Fynomers ® , Centyrins ®; and KALBITOR®. In some embodiments, the antibody may lack the covalent modifications (e.g., glycan attachment) that would be present in naturally occurring antibodies. In some embodiments, the antibody may contain covalent modifications (e.g., glycan, payload (e.g., detectable portion, therapeutic portion, catalytic portion, etc.) or other dangling groups (e.g., polyethylene glycol, etc.) attachments).

[0126] As used herein, the term “antibody agent” generally refers to an agent that specifically binds to a particular antigen. In some embodiments, the term covers any polypeptide or polypeptide complex comprising sufficient immunoglobulin structural elements to confer specific binding. Exemplary antibody agents include, but are not limited to, monoclonal or polyclonal antibodies. In some embodiments, the antibody agent may comprise one or more constant region sequences characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, the antibody agent may comprise one or more sequence elements that are humanized, primate-derived, chimeric, etc., as known in the art. In many implementations, the term "antibody agent" is used to refer to a construct or form known or developed in the industry for utilizing the structural and functional characteristics of antibodies in alternative presentations. For example, the antibody agents utilized according to the present invention are selected from, but not limited to, the following forms: intact IgA, IgG, IgE, or IgM antibodies; bispecific or multispecific antibodies (e.g., Zybodies®, etc.); antibody fragments, such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd fragments, and isolated CDRs or collections thereof; single-chain Fv; peptide-Fc fusions; single-domain antibodies (e.g., shark single-domain antibodies, such as IgNAR or fragments thereof); camel antibodies; masking antibodies (e.g., Probodies®); small modular immunopharmaceuticals (SMIP™); single-chain or tandem biantibodies (TandAb®); VHH; Anticalins®; Nanobodies® microantibodies; BiTE®; ankyrin repeats or DARPINs®; Avimers®; DART; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies® TrimerX®; microproteins; Fynomers®, Centyrins®; and KALBITOR®.

[0127] The antibody or antibody agent used to perform the methods of this disclosure may be single-chain or double-chain. In some embodiments, the antibody or antigen-binding molecule is single-chain. In some embodiments, the antigen-binding molecule is selected from the following...Groups: scFv, Fab, Fab', Fv, F(ab')2, dAb, and any combination thereof.

[0128] Antibodies and antibody agents include antibody fragments. Antibody fragments contain a portion of a complete antibody, such as the antigen-binding region or variable region of a complete antibody. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, biantibodies, linear antibodies, multispecific antibodies formed from antibody fragments and scFv fragments, and other fragments. Antibodies also include, but are not limited to, polyclonal, monoclonal, chimeric dAb (domain antibody), single-chain, Fab, Fa, F(ab')2 fragments, and scFv. Antibodies can be complete antibodies, immunoglobulins, or antibody fragments. Antibody fragments can be prepared by a variety of techniques, including but not limited to the proteolytic digestion of complete antibodies and production by recombinant host cells (e.g., E. coli, Chinese hamster ovary (CHO) cells, or bacteriophages), as known in the art.

[0129] In some embodiments, the antibody or antibody agent may be a chimeric antibody (see, for example, U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). A chimeric antibody may be an antibody in which a portion of the heavy chain and / or light chain is derived from a particular source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species. In one example, a chimeric antibody may comprise a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate (such as a monkey)) and a human constant region. In another example, a chimeric antibody may be a “class-switching” antibody in which the class or subclass has been changed relative to the class or subclass of the parent antibody. A chimeric antibody includes its antigen-binding fragment.

[0130] In some embodiments, the chimeric antibody may be a humanized antibody (see, for example, Almagro and Fransson, Front. Biosci., 13:1619-1633 (2008); Riechmann et al., Nature, 332:323-329 (1988); Queen et al., Proc. Natl Acad. Sci. USA 86:10029-10033 (1989); U.S. Patents Nos. 5,821,337, 7,527,791, 6,982,321 and 7,087,409; Kashmiri et al., Methods 36: 25-34 (2005); Padlan, Mol. Immunol, 28:489-498 (1991); Dall'Acqua et al., Methods, 36: 43-60(2005); Osbourn et al., Methods, 36:61-68 (2005); and Klimka et al., Br. J. Cancer, 83:252-260 (2000). Humanized antibodies are chimeric antibodies that contain amino acid residues from a nonhuman hypervariable region and amino acid residues from a human FR. In some embodiments, the humanized antibody will contain at least one, and typically substantially all, of two variable domains, wherein all or substantially all of the hypervariable regions (e.g., CDR) correspond to the hypervariable region of the nonhuman antibody, and all or substantially all of the frame regions (FR) correspond to the frame regions of the human antibody. The humanized antibody may optionally contain at least a portion of the antibody constant region derived from the human antibody.

[0131] In some embodiments, the antibodies or antibody agents provided herein are human antibodies. Human antibodies can be produced using a variety of techniques known in the art, as described on pages 61 / 84 of CN 121532650 A (see, for example, van Dijk and van de Winkel, Curr. Opin. Pharmacol, 5: 368-74 (2001); and Lonberg, Curr. Opin. Immunol, 20: 450-459 (2008)). Human antibodies can be antibodies having an amino acid sequence corresponding to an antibody that is produced by a human or human cell, or derived from a non-human source utilizing a human antibody library or other antibody-encoding sequences. This definition of a human antibody explicitly excludes humanized antibodies containing non-human antigen-binding residues. Human antibodies can be prepared using methods well known in the art.

[0132] As used herein, the term "antibody agent" generally refers to an agent that specifically binds to a particular antigen. In some embodiments, the term covers any polypeptide or polypeptide complex containing sufficient immunoglobulin structural elements to confer specific binding. Exemplary antibody agents include, but are not limited to, monoclonal or polyclonal antibodies. In some embodiments, the antibody agent may comprise one or more constant region sequences characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, the antibody agent may comprise one or more sequence elements that are humanized, primate-derived, chimeric, etc., as known in the art. In many embodiments, the term "antibody agent" is used to refer to constructs or forms known or developed in the art for utilizing the structural and functional characteristics of antibodies in alternative presentations. For example, the antibody agents utilized according to the present invention are in the form of, but not limited to: intact IgA, IgG, IgE, or IgM antibodies; bispecific or multispecific antibodies (e.g., Zybodies®, etc.); antibody fragments, such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd fragments, and fractions.CDRs or sets thereof; single-chain Fvs; peptide-Fc fusions; single-domain antibodies (e.g., shark single-domain antibodies, such as IgNAR or fragments thereof); camel antibodies; masking antibodies (e.g., Probodies®); small modular immunotherapies (SMIP™); single-chain or tandem biantibodies (TandAb®); VHH; Anticalins®; Nanobodies® microantibodies; BiTE®; ankylosing repeats or DARPINs®; Avimers®; DART; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; microproteins; Fynomers®, Centyrins®; and KALBITOR®.

[0133] As used herein, a chimeric antigen receptor (CAR) is a protein that specifically recognizes a target antigen (e.g., a target antigen on a cancer cell). Upon binding to a target antigen, a CAR can activate immune cells to attack and destroy cells carrying that antigen (e.g., cancer cells). CARs can also be incorporated with co-stimulatory or signal transduction domains to increase their potency. See Krause et al., J. Exp. Med., Vol. 188, No. 4, 1998 (619–626); Finney et al., Journal of Immunology, 1998, 161: 2791–2797; Song et al., Blood 119:696–706 (2012); Kalos et al., Sci. Transl. Med. 3:95 (2011); Porter et al., N. Engl. J. Med. 365:725–33 (2011); and Gross et al., Annu. Rev. Pharmacol. Toxicol. 56:59–83 (2016); U.S. Patent Nos. 7,741,465 and 6,319,494.

[0134] The chimeric antigen receptor described herein comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises an antigen-binding domain that specifically binds to a target.

[0135] In some embodiments, the antigen-specific CAR further comprises a safety switch and / or one or more monoclonal antibody-specific epitopes.

[0136] 1. Antigen-binding domain As discussed above, the CAR described herein comprises an antigen-binding domain. As used herein, "antigen-binding domain" means any polypeptide that binds to a specified target antigen. In some embodiments, the antigen-binding domain binds to tumor cells.Antigen binding. In some embodiments, the antigen-binding domain binds to antigens on cells involved in hyperproliferative diseases. Specification 62 / 84 pages 65 CN 121532650 A

[0137] In some embodiments, the antigen-binding domain comprises a variable heavy chain, a variable light chain, and / or one or more CDRs described herein. In some embodiments, the antigen-binding domain is a single-chain variable fragment (scFv) comprising light chain CDRs CDR1, CDR2, and CDR3 and heavy chain CDRs CDR1, CDR2, and CDR3.

[0138] The antigen-binding domain is said to be “selective” when it binds more tightly or has a higher affinity to one target than to another.

[0139] The antigen-binding domain of a CAR selectively targets cancer antigens. In some implementations, the cancer antigen is selected from EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, sealing protein-18.2, Muc17, FAP α, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52, or CD34. In some implementations, the CAR includes antigen-binding domains targeting the following: EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, sealing protein-18.2, Muc17, FAP α, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52, or CD34.

[0140] In some embodiments, the cancer antigen is selected from the group consisting of: carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CDS, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD123, CD133, CD138, antigens of cytomegalovirus (CMV) infected cells (e.g., cell surface antigens), epithelial glycoprotein (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein.Kinases erb-B2,3,4, folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor, ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit α-2 (IL-13Ra2), κ-light chain, kinase insertion domain receptor (KDR), Lewis A (CA19.9), LI cell adhesion molecule (LICAM), melanoma antigen family A,1 (MAGE-AI), mucin 16 (Muc-16), mucin 1 (Muc-1), mesothelin (MSLN), NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-72). R2) and nephroblastoma protein (WT-1).

[0141] Variants of the antigen-binding domain (e.g., variants of CDR, VH, and / or VL) are also within the scope of this disclosure, for example, variant light chains and / or variant heavy chains having at least 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, 97-99%, or higher than 99% identity with the amino acid sequence of the antigen-binding domain. In some cases, such molecules comprise at least one heavy chain and one light chain, while in others, the variant forms contain two variant light chains and two variant heavy chains (or sub-parts thereof). Those skilled in the art will be able to determine suitable variants of the antigen-binding domain as shown herein using well-known techniques. In some embodiments, those skilled in the art can identify suitable regions in the molecule that can change without destroying activity by targeting regions considered unimportant to activity.

[0142] In some embodiments, the polypeptide structure of the antigen-binding domain is based on an antibody, including but not limited to monoclonal antibodies, bispecific antibodies, microantibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof. In some embodiments, the antigen-binding domain comprises or is composed of an avimer.

[0143] In some embodiments, the antigen-binding domain is an scFv.

[0144] In some embodiments, the antigen-selective CAR comprises a leader sequence or a signal peptide.

[0145] In other embodiments, this disclosure relates to isolated polynucleotides encoding any of the antigen-binding domains described herein. In some embodiments, this disclosure relates to isolated polynucleotides encoding CARs. A specification is also provided herein.Pages 63 / 84, 66 CN 121532650 A Vectors containing polynucleotides, and methods for preparing the same.

[0146] In other embodiments, this disclosure relates to isolated polynucleotides encoding any of the antigen-binding domains described herein. In some embodiments, this disclosure relates to isolated polynucleotides encoding CARs. Vectors containing polynucleotides are also provided herein, and methods for preparing the same.

[0147] In some embodiments, CAR-immune cells (e.g., CAR-T cells) that can form components of engineered immune cell populations (derived from donor cells of donor cell populations as described herein) generated by practicing the methods of this disclosure contain polynucleotides encoding safety switch polypeptides (e.g., RQR8). See, for example, WO2013153391A, which is hereby incorporated by reference in its entirety. In CAR-immune cells (e.g., CAR-T cells) containing said polynucleotides, the safety switch polypeptide can be expressed on the surface of the CAR-immune cells (e.g., CAR-T cells).

[0148] 2. Hinge Domain The extracellular domain of the CAR disclosed herein may include a “hinge” domain (or hinge region). The term generally refers to any polypeptide that acts to link a transmembrane domain in the CAR to an extracellular antigen-binding domain in the CAR. Specifically, the hinge domain may be used to provide greater flexibility and accessibility to the extracellular antigen-binding domain.

[0149] The hinge domain may contain up to 300 amino acids, 10 to 100 amino acids in some embodiments, or 25 to 50 amino acids in some embodiments. The hinge domain may be derived from all or part of a naturally occurring molecule, such as all or part of an extracellular region derived from CD8, CD4, CD28, 4-1BB, or IgG (particularly the hinge region of IgG; it will be understood that the hinge region may contain some or all of members of the immunoglobulin family, such as IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, or fragments thereof), or from all or part of a constant region of an antibody heavy chain. Alternatively, the hinge domain may be a synthetic sequence corresponding to a naturally occurring hinge sequence, or it may be a fully synthetic hinge sequence. In some embodiments, the hinge domain is a portion of the human CD8α chain (e.g., NP_001139345.1). In other embodiments, the hinge and transmembrane domain comprise a portion of the human CD8α chain. In some embodiments, the hinge domain of the CAR described herein comprises a subsequence of CD8α, CD28, IgG1, IgG4, PD-1, or FcγRIIIα, particularly the hinge region of any one of CD8α, CD28, IgG1, IgG4, PD-1, or FcγRIIIα. In some embodiments, the hinge domain comprises a human CD8α hinge.The CAR disclosed herein comprises a CD8α hinge, a human IgG1 hinge, a human IgG4 hinge, a human PD-1 hinge, or a human FcγRIIIα hinge. In some embodiments, the CAR disclosed herein comprises scFv, a CD8α human hinge and a transmembrane domain, a CD3ζ signaling domain, and a 4-1BB signaling domain.

[0150] In some embodiments, the hinge domain in the CAR of this disclosure is a CD8α transmembrane domain. In some embodiments, the hinge domain in the CAR of this disclosure is a CD8α hinge domain comprising the amino acid sequence PTTTPAPRPPT PAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 332) or TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 340). In some embodiments, the CD8α hinge domain comprises a nucleic acid sequence encoding the hinge amino acid sequence of SEQ ID NO: 332. In some embodiments, the hinge domain in the CAR of this disclosure is the CD28 hinge domain.

[0151] 3. Transmembrane Domain The CAR of this disclosure is designed to have a transmembrane domain fused to the extracellular domain of the CAR. It may similarly fuse to the intracellular domain of the CAR. In some cases, the transmembrane domain may be selectively or modified by amino acid substitution to prevent such domains from binding to the transmembrane domains of the same or different surface membrane proteins, thereby minimizing interactions with other members of the receptor complex. In some embodiments, short linkers may form links between any or some of the extracellular domain, transmembrane domain, and intracellular domain of the CAR.

[0152] The transmembrane domain suitable for the CAR disclosed herein has the following capabilities: (a) expression at the surface of immune cells such as, but not limited to, lymphocytes, such as T helper (Th) cells, cytotoxic T (Tc) cells, T regulatory (Treg) cells, or natural killer (NK) cells; and / or (b) interaction with extracellular antigen-binding domains and intracellular signal transduction domains to guide the cellular response of immune cells against target cells.

[0153] The transmembrane domain may be derived from a natural source or a synthetic source. In the case of a natural source, the domain may be derived from any membrane-binding protein or transmembrane protein.

[0154] The transmembrane region used in particular in this disclosure may be derived from (including or correspond to) CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed death receptor-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1.(LFA-1, CD1-1a / CD18), CD3γ, CD3δ, CD3ε, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptor, MHC class 1 molecules, TNF receptor protein, immunoglobulin, cytokine receptor, integrin, signal transduction lymphocyte activating molecule (SLAM protein), activating NK cell receptor, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ , IL‑7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA‑6, CD49f, ITGAD, CD1 1d, ITGAE, CD103, ITGAL, CD1 1a, LFA‑1, ITGAM, CD1 1b, ITGAX, CD1 1c, ITGB1, CD29, ITGB2, CD18, LFA‑1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, ligands that specifically bind to CD83, or any combination thereof.

[0155] As a non-limiting example, the transmembrane domain may be derived from or a subset of: T cell receptors, such as α, β, γ, or δ; polypeptides constituting the CD3 complex; IL-2 receptor p55 (α chain), p75 (β chain), or γ chain; Fc receptors, particularly subunit chains of Fc γ receptor III; or CD proteins. Alternatively, the transmembrane domain may be synthetic and may primarily comprise hydrophobic residues, such as leucine and valine. In some embodiments, the transmembrane domain is derived from the human CD8α chain (e.g., NP_001139345.1).

[0156] In some embodiments, the transmembrane domain in the CAR of this disclosure is a CD8α transmembrane domain. In some embodiments, the transmembrane domain in the CAR of this disclosure is a CD8α transmembrane domain comprising the amino acid sequence IYIWAPLAGTCGVLLLSLVIT or IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 333). In some embodiments, the CD8α transmembrane domain comprises a nucleic acid sequence encoding the transmembrane amino acid sequence of IYIWAPLAGTCGVLLLSLVIT or SEQ ID NO: 333. In some embodiments, the hinge and transmembrane domain in the CAR of this disclosure are CD8α hinge and transmembrane domains comprising the amino acid sequence of SEQ ID NO: 323 or TTTPAPRPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD IYIWAPLAGTCGVLLLSLVIT.

[0157] In some embodiments, the transmembrane domain in the CAR of this disclosure is a CD28 transmembrane domain.

[0158] 4. Intracellular Domain The intracellular (cytoplasmic) domain of the CAR disclosed herein can provide activation of at least one of the normal effector functions of the immune cell containing the CAR. For example, T cell effector functions can refer to cytolytic activity or helper activity, including the secretion of cytokines.

[0159] In some embodiments, the activating intracellular signal transduction domain for use in the CAR can be, for example, but not limited to, cytoplasmic sequences of T cell receptors and helper receptors that work synergistically to initiate signal transduction upon antigen receptor binding, as well as any derivatives or variants of these sequences and any synthetic sequences having the same functional capabilities.

[0160] It will be understood that suitable (e.g., activating) intracellular domains include, but are not limited to, signal transduction domains derived from (or corresponding to) pages 65 / 84 of the following specification, CN 121532650 A: CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed death receptor-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CD1-1a / CD18), CD3γ, CD3δ, CD3ε, CD247, CD276 (B7-H3), LIGHT (TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptor, MHC class 1 molecules, TNF receptor proteins, immunoglobulins, cytokine receptors, integrins, signal transduction domains, etc.Lymphocyte activating molecule (SLAM protein), activating NK cell receptor, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD1 1c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (tactile protein), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, ligands that specifically bind to CD83, or any combination thereof.

[0161] In addition to the activating domains described above, the intracellular domains of the CAR of this disclosure may also incorporate co-stimulatory signal transduction domains (which are interchangeably referred to herein as co-stimulatory molecules) to increase their potency. In addition to the primary signal provided by the stimulatory molecules as described herein, the co-stimulatory domains can provide signals.

[0162] It will be understood that suitable costimulatory domains within the scope of this disclosure may be derived from (or correspond to), for example, CD28, OX40, 4-1BB / CD137, CD2, CD3 (α, β, δ, ε, γ, ζ), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD33, CD37, CD40, CD45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a / CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor).Superfamily member 14; TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptor, MHC class I molecules, TNFR, integrins, signal transduction lymphocyte activating molecules, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6. VLA‑6, CD49f, ITGAD, CD1‑1d, ITGAE, CD103, ITGAL, CD1‑1a, LFA‑1, ITGAM, CD1‑1b, ITGAX, CD1‑1c, ITGB1, CD29, ITGB2, CD18, LFA‑1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (tactin), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB‑A, Ly108), SLAM (SLAMF1, CD150, IPO‑3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligands, or fragments or combinations thereof. It will be understood that other co-stimulatory molecules or fragments thereof not listed above are within the scope of this disclosure.

[0163] In some embodiments, the intracellular / cytoplasmic domain of the CAR may be designed to include a 4-1BB / CD137 domain, alone or in combination with any other one or more desired intracellular domains useful in the context of the CAR of this disclosure. The complete native amino acid sequence of 4-1BB / CD137 is described in NCBI reference sequence: NP_001552.2. The complete native 4-1BB / CD137 nucleic acid sequence is described in NCBI reference sequence: NM_001561.5.

[0164] In some embodiments, the intracellular / cytoplasmic domain of the CAR may be designed to include a CD28 domain, alone or in combination with any other one or more desired intracellular domains useful in the context of the CAR of this disclosure.The complete natural amino acid sequence of CD28 is described in NCBI reference sequence: NP_006130.1. The complete natural CD28 nucleic acid sequence is described in NCBI reference sequence: NM_006139.1. Specification 66 / 84 pages 69 CN 121532650 A

[0165] In some embodiments, the intracellular / cytoplasmic domain of the CAR may be designed to include a CD3ζ domain alone or in combination with any other one or more desired intracellular domains useful in the context of the CAR of this disclosure.

[0166] For example, the intracellular domain of the CAR may include a portion of the CD3ζ chain and a portion of a co-stimulatory signaling molecule. The intracellular signaling sequences within the intracellular signaling portion of the CAR of this disclosure may be linked to each other in a random or designated order. In some embodiments, the intracellular domain is designed to include an activating domain of CD3ζ and a signaling domain of CD28. In some embodiments, the intracellular domain is designed to include an activating domain of CD3ζ and a signaling domain of 4-1BB.

[0167] In some embodiments, the intracellular signaling domain of the CAR of this disclosure includes a domain of a co-stimulatory molecule. In some embodiments, the intracellular signaling domain of the CAR of this disclosure includes a portion of a co-stimulatory molecule selected from the group consisting of fragments of 4-1BB (GenBank: AAA53133.) and CD28 (NP_006130.1).

[0168] Table 3 provides exemplary sequences of CAR components that can be used in the CARs disclosed herein, as well as antibody and / or CAR sequences exemplified herein.

[0169] Table 3: CAR-related sequences Specification 67 / 84 pages 70 CN 121532650 A Specification 68 / 84 pages 71 CN 121532650 A Specification 69 / 84 pages 72 CN 121532650 A

[0170] Table 4 provides exemplary sequences of chimeric cytokine receptor (CCR) components that can be used in the CCRs disclosed herein. CCR may be expressed together with a signal sequence (e.g., CD8SS of the sequence MALVTALLLPLALLLHAARP (SEQ ID NO: 127)). See specification 70 / 84 pages 73 CN 121532650 A.

[0171] Table 4 – CCR Sequences

[0172] Table 5 provides exemplary CACCR sequences with or without anti-BCMA CAR showing a P2A linker sequence (GSGATNFSLLKQAGDVEENPG (SEQ ID NO: 307)).

[0173] Table 5 – CACCR Sequences with P2A Linker Sequences (Specification 71 / 84 pages 74)CN 121532650 A

[0174] Engineered Immune Cells Containing CARs This document also provides engineered immune cells and populations of engineered immune cells that i) contain polynucleotides encoding a bicistronic expression polypeptide, a linker peptide, and other polypeptides (e.g., CAR), and / or ii) express a bicistronic expression polypeptide, a linker peptide, and other polypeptides, such as CARs (e.g., CAR-T cells or CAR+ cells).

[0175] In some embodiments, the engineered immune cells comprise CAR T cells, each CAR T cell containing an extracellular antigen-binding domain and having reduced or eliminated expression of endogenous TCR. In some embodiments, the population of engineered immune cells comprises a population of CAR T cells, each CAR T cell containing two or more distinct extracellular antigen-binding domains and having reduced or eliminated expression of endogenous TCR. In some embodiments, the immune cells comprise a population of CARs, each CAR T cell containing the same extracellular antigen-binding domain and having reduced or eliminated expression of one or more desired biomarkers (as described herein) and / or endogenous TCR.

[0176] The engineered immune cells can be allogeneic or autologous. Specification 72 / 84 pages 75 CN 121532650 A

[0177] In some embodiments, the engineered immune cells or populations of engineered immune cells are T cells (e.g., inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes, helper T lymphocytes, tumor-infiltrating lymphocytes (TILs)), NK cells, NK-T cells, TCR-expressing cells, dendritic cells, cytotoxic dendritic cells, mast cells, or B cells, and express CAR. In some embodiments, the T cells can be derived from the group consisting of CD4+ T lymphocytes, CD8+ T lymphocytes, or a population comprising a combination of CD4+ and CD8+ T cells.

[0178] In some embodiments, the engineered immune cells or populations of engineered immune cells generated using the disclosed methods can be derived from, for example, but not limited to, stem cells. Stem cells can be adult stem cells, non-human embryonic stem cells (more specifically, non-human stem cells), umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells, or hematopoietic stem cells.

[0179] In some embodiments, the engineered immune cells or populations of immune cells generated using the disclosed methods are obtained or prepared from peripheral blood. In some embodiments, the engineered immune cells are obtained or prepared from peripheral blood mononuclear cells (PBMCs). In some embodiments, the engineered immune cells are obtained or prepared from bone marrow. In some embodiments, the engineered immune cells are obtained or prepared from umbilical cord blood. In some embodiments, donor cells...Human cells. In some embodiments, donor cells are transfected or transduced via nucleic acid vectors using methods selected from the group consisting of: electroporation, acoustic pore effect, gene gun method (e.g., gene gun), lipid transfection, polymer transfection, nanoparticles, viral transfection (e.g., retrovirus, lentivirus, AAV), or polymeric complexes.

[0180] In some embodiments, engineered immune cells expressing antigen-specific CARs on cell surface membranes comprise greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of stem cell memory cells and central memory cells.

[0181] In some embodiments, engineered immune cells expressing antigen-specific CARs on cell surface membranes comprise the following percentages of stem cell memory cells and central memory cells: about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 15% to about 50%, about 15% to about 40%, about 20% to about 60%, or about 20% to about 70%.

[0182] In some embodiments, engineered immune cells expressing antigen-specific CARs on cell surface membranes are enriched with TCM cells and / or TSCM cells, such that the engineered immune cells comprise at least about 60%, 65%, 70%, 75%, or 80% of a combination of TCM cells and TSCM cells. In some embodiments, engineered immune cells expressing antigen-specific CARs on cell surface membranes are enriched with TCM cells and / or TSCM cells, such that the engineered immune cells comprise at least about 70% of a combination of TCM cells and TSCM cells. In some embodiments, engineered immune cells expressing antigen-specific CARs on cell surface membranes are enriched with TCM cells and / or TSCM cells, such that the engineered immune cells comprise at least about 75% of a combination of TCM cells and / or TSCM cells.

[0183] In some embodiments, the engineered immune cells are CAR-expressing inflammatory T lymphocytes. In some embodiments, the engineered immune cells are CAR-expressing cytotoxic T lymphocytes. In some embodiments, the engineered immune cells are CAR-expressing regulatory T lymphocytes. In some embodiments, the engineered immune cells are helper T lymphocytes expressing CAR.

[0184] Genetic modification of CAR T cells In some embodiments, engineered immune cells derived from donor cells having a certain biomarker profile according to this disclosure may contain one or more disrupted or inactivated genes. In some embodiments, target antigens (e.g., EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, etc.) may be knocked out.MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, sealing protein-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, or CD34, CD70) are the base antigens for introducing targeting the same antigens (e.g., EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, etc.). (See page 73 / 84 of the specification, CN 121532650 A). ROR1, sealing protein-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, or CD34, CD70 CAR) CAR, thereby avoiding induced CAR activation. As described herein, in some embodiments, engineered immune cells according to this disclosure comprise a disrupted or inactivated gene selected from the group consisting of: MHC1 (β2M), MHC2 (CIITA), EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, sealing protein-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, or CD34, CD70, TCRα, and TCRβ, and / or express a CAR or multi-chain CAR. In some embodiments, the cells comprise a multi-chain CAR. In some embodiments, the isolated cells contain two disrupted or inactivated genes selected from the group consisting of: CD52 and TCRα, CD52 and TCRβ, PD-1 and TCRα, PD-1 and TCRβ, MHC-1 and TCRα, MHC-1 and TCRβ, MHC2 and TCRα, MHC2 and TCRβ, and / or express CAR or multi-chain CAR.

[0185] In some embodiments, the isolated cells contain a polynucleotide encoding a polypeptide comprising a multi-chain CAR. In some embodiments, the isolated cells according to this disclosure contain two disrupted or inactivated genes selected from the group consisting of:Because: CD52 and GR, CD52 and TCRα, CDR52 and TCRβ, DLL3 and CD52, DLL3 and TCRα, DLL3 and TCRβ, GR and TCRα, GR and TCRβ, TCRα and TCRβ, PD-1 and TCRα, PD-1 and TCRβ, CTLA-4 and TCRα, CTLA-4 and TCRβ, LAG3 and TCRα, LAG3 and TCRβ, TIM3 and TCRα, Tim3 and TCRβ, BTLA and TCRα, BTLA and TCRβ, BY55 and TCRα, BY55 and TCRβ, TIGIT and TCRα, TIGIT and TCRβ, B7H5 and TCRα, B7H5 and TCRβ, LAIR1 and TCRα, LAIR1 and TCRβ, SIGLEC10 and TCRα, SIGLEC10 and TCRβ, 2B4 and TCRα, 2B4 and TCRβ, and / or expression of CAR (including multi-stranded CAR) and / or pTα transgenes. In some embodiments, the method includes destroying or inactivating one or more genes by introducing a nuclease capable of selectively inactivating the gene through selective DNA cleavage into donor cells. In some embodiments, the nuclease may be, for example, a zinc finger nuclease (ZFN), a megaTAL nuclease, a meganucleotide nuclease, a transcription activator-like effector nuclease (TALE nuclease or TALEN®), or a CRISPR (e.g., Cas9 or Cas12) nuclease.

[0186] In some embodiments, TCRs are rendered nonfunctional in cells according to the present disclosure by destroying or inactivating the TCRα gene and / or one or more TCRβ genes. In some embodiments, a method is provided for obtaining modified cells derived from an individual, wherein the cells can proliferate independently of the major histocompatibility complex (MHC) signaling pathway. Modified cells that can proliferate independently of MHC signaling pathways and are readily obtainable by this method are covered within the scope of this disclosure. The modified cells disclosed herein can be used for patients in need of treatment against host-vG rejection and graft-versus-host disease (GvHD); therefore, the scope of this disclosure includes methods for treating patients in need of treatment against host-vG rejection and graft-versus-host disease (GvHD), said methods comprising treating said patients by administering an effective amount of modified cells containing a destroyed or inactivated TCRα and / or TCRβ gene.

[0187] This disclosure provides a method for determining the purity of a population of engineered immune cells lacking or having reduced endogenous TCR expression. In some embodiments, the engineered immune cells comprise less than 5.0%, less than 4.0%, less than 3.0% TCR+ cells, less than 2.0% TCR+ cells, less than 1.0% TCR+ cells, less than 0.9% TCR+ cells, etc.TCR+ cells, less than 0.8% TCR+ cells, less than 0.7% TCR+ cells, less than 0.6% TCR+ cells, less than 0.5% TCR+ cells, less than 0.4% TCR+ cells, less than 0.3% TCR+ cells, less than 0.2% TCR+ cells, or less than 0.1% TCR+ cells. This population may be a product of the disclosed methods.

[0188] In some embodiments, immune cells are engineered to be resistant to one or more chemotherapeutic agents. The chemotherapeutic agents may be, for example, purine nucleotide analogs (PNAs), thereby making the immune cells suitable for cancer treatment in combination with adoptive immunotherapy and chemotherapy. Exemplary PNAs include, for example, clofarabine, fludarabine, cyclophosphamide, and cytarabine, alone or in combination. PNAs are metabolized by deoxycytidine kinase (dCK) to monophosphate, diphosphate, and triphosphate PNAs. Their triphosphate forms compete with ATP for DNA synthesis, act as pro-apoptotic agents, and are potent inhibitors of ribonucleotide reductases (RNRs) involved in trinucleotide production.

[0189] In some embodiments, the isolated cells or cell lines of this disclosure may contain pTα or functional variants thereof. In some embodiments, the isolated cells or cell lines may be further genetically modified by disrupting or inactivating the TCRα gene.

[0190] This disclosure also provides engineered immune cells containing polynucleotides encoding bicistronic expression polypeptides, linker peptides, and any CAR polypeptides described herein. In some embodiments, CARs may be introduced into immune cells as transgenes via plasmid vectors. In some embodiments, the plasmid vectors may also contain, for example, selection markers that provide identification and / or selection of cells receiving the vector.

[0191] CAR polypeptides may be synthesized in situ in cells after the introduction of polynucleotides encoding CAR polypeptides into cells. Alternatively, CAR polypeptides may be generated outside the cells and then introduced into the cells. Methods for introducing polynucleotide constructs into cells are known in the art. In some embodiments, a stable transformation method (e.g., using a lentiviral vector) can be used to integrate the polynucleotide construct into the cellular genome. In other embodiments, a transient transformation method can be used to transiently express the polynucleotide construct, as well as the polynucleotide construct not integrated into the cellular genome. In other embodiments, a virus-mediated method can be used. The polynucleotide can be introduced into the cell by any suitable means, such as, for example, recombinant viral vectors (e.g., retroviruses, adenoviruses), liposomes, etc. Transient transformation methods include, for example, but not limited to, microinjection, electroporation, or particle bombardment. The polynucleotide can be included in a vector (e.g., a plasmid vector or a viral vector).

[0192] In some embodiments, an isolated nucleic acid is provided comprising a promoter operatively linked to a first polynucleotide encoding an antigen-binding domain, at least one co-stimulatory molecule, and an activating domain. In some embodiments, the nucleic acid construct is contained within a viral vector. In some embodiments, the viral vector is selected from the group consisting of: retroviral vectors, murine leukemia virus vectors, SFG vectors, adenovirus vectors, lentiviral vectors, adeno-associated virus (AAV) vectors, herpesvirus vectors, and vaccinia virus vectors. In some embodiments, the nucleic acid is contained within a plasmid.

[0193] In some embodiments, the isolated nucleic acid construct is contained within a viral vector and introduced into the genome of engineered immune cells via random integration (e.g., random integration mediated by lentivirus or retrovirus). In some embodiments, the isolated nucleic acid construct is contained within a viral vector or a non-viral vector and introduced into the genome of engineered immune cells via site-specific integration (e.g., site-specific integration mediated by adenovirus).

[0194] Manufacturing of Engineered Immune Cells (Including CAR T Cells) This document provides methods for analyzing or determining various properties of donor cells from a donor cell population and / or engineered immune cells from a population of immune cells (including engineered immune cells, such as cells expressing CAR or CAR+ cells). As described herein, engineered immune cells (such as CAR T cells) may be modified to reduce or eliminate the expression or activity of endogenous TCRs, and at the end of manufacturing, any remaining TCR+ engineered immune cells may be depleted according to the methods described herein. This disclosure provides methods for characterizing or analyzing populations of engineered immune cells to characterize a pharmaceutical product or as part of a manufacturing process. This disclosure also provides methods for analyzing or determining other properties of engineered immune cells (such as potency or versatility) to characterize a pharmaceutical product or as part of a manufacturing process. In some embodiments, engineered immune cells (such as CAR T cells) are manufactured according to Good Manufacturing Practice (GMP).

[0195] Various known techniques can be used in the preparation of polynucleotides, peptides, vectors, antigen-binding domains, immune cells, compositions, etc. according to the present disclosure, page 75 / 84, CN 121532650 A.

[0196] The cells described herein can be obtained from a subject prior to in vitro manipulation or genetic modification of the immune cells. Cells expressing CAR can be derived from allogeneic or autologous sources and can deplete endogenous TCRs as described herein.

[0197] 1. Source Materials In some embodiments, the immune cells include T cells. T cells can be obtained from a variety of sources, including peripheral blood.Mononuclear cells (PBMCs), bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from sites of infection, ascites, pleural effusion, spleen tissue, and tumors. In some embodiments, T cells can be obtained from a volume of blood collected from a subject using any number of techniques known to those skilled in the art (such as FICOLL™ isolation).

[0198] Cells can be obtained from an individual's circulating blood via apheresis. Apheresis products typically contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In some embodiments, cells collected via apheresis can be washed to remove plasma fractions and then placed in a suitable buffer or medium for further processing.

[0199] In some embodiments, T cells are isolated from PBMCs by lysing erythrocytes and depleting monocytes (e.g., using centrifugation via a PERCOLL™ gradient). Specific subsets of T cells (e.g., CD28+, CD4+, CD45RA-, and CD45RO+ T cells or CD28+, CD4+, CD5RA-, CD45RO+, and CD62L+ T cells) can be further isolated using positive or negative selection techniques known in the art. For example, enriching a T cell population by negative selection can be accomplished using a combination of antibodies against surface markers specific to the negatively selected cells. One method used herein is cell sorting and / or selection or flow cytometry via negative magnetic immunoadsorption, using a mixture of monoclonal antibodies against cell surface markers present on the negatively selected cells. For example, to enrich CD4+ cells by negative selection, the monoclonal antibody mixture typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. Flow cytometry and cell sorting can also be used to isolate a target cell population for use in this disclosure.

[0200] PBMCs can be directly used for genetic modification with immune cells (such as CARs or TCRs) as described herein. In some embodiments, after isolating PBMCs, and before or after genetic modification and / or expansion, T lymphocytes can be further isolated, and both cytotoxic and helper T lymphocytes can be sorted into naive, memory, and effector T cell subsets. In some embodiments, CD8+ cells are further sorted into naive, stem cell memory, central memory, and effector cells by identifying cell surface antigens associated with each of these types of CD8+ cells. In some embodiments, the expression of phenotypic markers for central memory T cells includes CD27, CD45RA, CD45RO, CD62L, CCR7, CD28, CD3, and CD127, and they are negative for granzyme B. In some embodiments, stem cell memory T cells are CD45RO-, CD62L...+, CD8+ T cells. In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In some embodiments, CD4+ T cells are further sorted into subsets. For example, CD4+ T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations with cell surface antigens.

[0201] 2. Stem cell-derived immune cells In some embodiments, immune cells may be derived from embryonic stem (ES) cells or induced pluripotent stem (iPS) cells. Suitable HSCs, mesenchymal, iPS cells, and other types of stem cells may be cultured immortalized cell lines or directly isolated from a patient. Various methods for isolating, developing, and / or culturing stem cells are known in the art and may be used in practice with respect to this disclosure.

[0202] In some embodiments, immune cells are induced pluripotent stem cells (iPSCs) derived from reprogrammed T cells. In some embodiments, as described on pages 76 / 84 of the specification (CN 121532650 A), the source material may be induced pluripotent stem cells (iPSCs) derived from T cells or non-T cells. The source material may be embryonic stem cells. The source material may be B cells, or any other cells derived from peripheral blood mononuclear cell isolates, hematopoietic progenitor cells, hematopoietic stem cells, mesenchymal stem cells, adipose stem cells, or any other somatic cell type.

[0203] 3. Genetic Modification of Isolated Cells The donor immune cells (e.g., T cells) of the isolated cell population may be genetically modified using known methods after isolation, or the donor immune cells may be activated and expanded in vitro (or differentiated in the case of progenitor cells) prior to genetic modification. In some embodiments, the isolated donor immune cells are genetically modified to reduce or eliminate the expression or activity of endogenous TCRα and / or CD52. In some embodiments, the cells are genetically modified using gene-editing technologies (e.g., CRISPR / Cas9, CRISPR / Cas12a, zinc finger nucleases (ZFN), TALEN, MegaTAL, mega-nucleases, base editing, or guided editing) to reduce or eliminate the expression or activity of endogenous proteins (e.g., TCRα and / or CD52). In another embodiment, immune cells (such as T cells) are genetically modified with the chimeric antigen receptor described herein (e.g., transduced with a viral vector containing one or more nucleotide sequences encoding a CAR), and then activated and / or expanded in vitro.

[0204] Certain methods for preparing the constructs and engineered immune cells of this disclosure are described in PCT application PCT / US15 / 14520, the contents of which are hereby incorporated by reference in their entirety.

[0205] It will be understood that PBMCs may also include other cytotoxic lymphocytes, such as NK cells or NKT cells. Expression vectors carrying coding sequences for chimeric receptors as disclosed herein can be introduced into populations of human donor T cells, NK cells, or NKT cells. Successfully transduced T cells carrying expression vectors can be sorted by flow cytometry to isolate CD3-positive T cells, in addition to cell activation using anti-CD3 antibodies and IL-2 or other methods known in the art as described elsewhere herein, and then further proliferated to increase the number of these CAR-expressing T cells. CAR-expressing T cells are cryopreserved using standard procedures for storage and / or preparation for use in human subjects. In one embodiment, in vitro transduction, culture, and / or expansion of T cells are performed in the absence of products of non-human animal origin, such as fetal calf serum and fetal bovine serum.

[0206] For polynucleotide cloning, vectors can be introduced into host cells (isolated host cells) to allow the vector to replicate itself, thereby amplifying the copy number of the polynucleotides contained in the vector. Cloning vectors may contain sequence components, typically including but not limited to origin of replication, promoter sequences, transcription initiation sequences, enhancer sequences, and selectability markers. These elements may be selected by those skilled in the art as appropriate. For example, the origin of replication may be selected to facilitate autonomous replication of the vector in a host cell.

[0207] In some embodiments, this disclosure provides isolated host cells containing the vector provided herein. Host cells containing the vector can be used for the expression or cloning of the polynucleotide contained in the vector. Suitable host cells may include, but are not limited to, prokaryotic cells, fungal cells, yeast cells, or higher eukaryotic cells (such as mammalian cells), particularly human cells.

[0208] The vector may be introduced into a host cell using any suitable method known in the art, including but not limited to DEAE-dextran-mediated delivery, calcium phosphate precipitation, cationic lipid-mediated delivery, liposome-mediated transfection, electroporation, microparticle bombardment, receptor-mediated gene delivery, and delivery mediated by polylysine, histones, chitosan, and peptides. Standard methods for transfection and transformation of cells expressing the target vector are well known in the art. In another embodiment, a mixture of different expression vectors, each encoding a different CAR as disclosed herein, may be used when genetically modifying a donor population of immune effector cells. The resulting transduced immune effector cells form a mixed population of engineered cells, a subset of which express more than one different CAR.

[0209] In one embodiment, this disclosure provides a method for sorting genetically engineered cells expressing CAR or TCR.Method. This method involves cryopreservation of immune cells, allowing the cells to remain viable after thawing. A subset of CAR-expressing immune cells can be cryopreserved using the method described in the specification 77 / 84 pages 80 CN 121532650 A, known in the art, to provide a permanent source of such cells for future treatment of patients with malignant tumors. When needed, the cryopreserved transformed immune cells can be thawed, grown, and expanded to obtain more of these cells.

[0210] In some embodiments, the cells are formulated by first harvesting the cells from a culture medium, then washing and concentrating the cells in a therapeutically effective amount in a media and container system suitable for administration (“pharmaceuticalally acceptable” carrier). Suitable infusion media can be any isotonic formulation, typically physiological saline, Normosol™ R (Abbott), or Plasma-Lyte™ A (Baxter), but 5% dextran aqueous solution or Ringer’s lactate may also be used. The infusion media may be supplemented with human serum albumin.

[0211] 4. Allogeneic CAR T cells: The process for manufacturing allogeneic CAR T therapy involves harvesting healthy, selected, screened, and tested donor immune cells (including T cells) from a healthy donor. Next, the donor immune cells' T cells are engineered to express CARs, which recognize certain cell surface proteins expressed in hematologic malignancies or solid tumors. The allogeneic T cells are genetically edited to reduce the risk of graft-versus-host disease (GvHD) and prevent allogeneic rejection. T cell receptor genes (e.g., TCR α, TCR β) are knocked out to avoid GvHD. The CD52 gene can be knocked out to make the CAR T product resistant to anti-CD52 antibody therapy. Therefore, anti-CD52 antibody therapy can be used to suppress the host immune system and allow CAR T cells to remain transplanted for complete therapeutic effect. The engineered T cells then undergo further processing, which may optionally include a depletion step for removing unwanted T cells expressing the biomarkers described herein (e.g., unwanted T cells expressing the TCR gene), a purification step, and finally cryopreservation of the T cells in vials for delivery to a patient.

[0212] 5. Autologous CAR T Cells Autologous chimeric antigen receptor (CAR) T cell therapy involves collecting cells (e.g., white blood cells, including T cells) from a patient and genetically engineering the T cells to express a CAR that recognizes a target expressed on the cell surface of one or more specific cancer cells and kills the cancer cells. The engineered cells are then cryopreserved and subsequently administered to a patient.

[0213] In Vitro Sorting Methods In some embodiments, methods are provided for the in vitro sorting of immune cell populations, wherein the immune cell populationsA subset of the body comprises engineered immune cells expressing an antigen-specific CAR, the antigen-specific CAR comprising an epitope (e.g., an exemplary mimic epitope sequence) specific to a monoclonal antibody. The method includes contacting a population of immune cells with a monoclonal antibody specific to the epitope, and selecting immune cells that bind to the monoclonal antibody to obtain a cell population enriched with engineered immune cells expressing the antigen-specific CAR.

[0214] In some embodiments, the monoclonal antibody specific to the epitope is optionally conjugated to a fluorophore. In this embodiment, the step of selecting cells that bind to the monoclonal antibody can be performed by fluorescence-activated cell sorting (FACS).

[0215] In some embodiments, the monoclonal antibody specific to the epitope is optionally conjugated to magnetic particles. In this embodiment, the step of selecting cells that bind to the monoclonal antibody can be performed by magnetically activated cell sorting (MACS).

[0216] In some embodiments, the mAb used in the method for sorting immune cells expressing CAR is selected from alemtuzumab, ibritumomab tiuxetan, muromonab-CD3, tositumomab, abciximab, basiliximab, brentuximab vedotin, cetuximab, infliximab, rituximab, bevacizumab, certolizumab (see specification page 78 / 84, 81 CN 121532650 A pegol), daclizumab, and eculizumab. b) Efalizumab, Gemtuzumab, Natalizumab, Omalizumab, Palivizumab, Ranibizumab, Tocilizumab, Trastuzumab, Vedolizumab, Adalimumab, Belimumab, Canakinumab, DenosumabGolimumab, ipilimumab, ofatumumab, panitumumab, QBEND-10, and / or ustekinumab. In some embodiments, the mAb is rituximab. In another embodiment, the mAb is QBEND-10. In other embodiments, the mAb binds to TCRα or TCRβ.

[0217] In some embodiments, the population of CAR-expressing immune cells obtained using the above-described method for in vitro sorting of CAR-expressing immune cells comprises at least 70%, 75%, 80%, 85%, 90%, and 95% CAR-expressing immune cells. In some embodiments, the population of CAR-expressing immune cells obtained using the method for in vitro sorting of CAR-expressing immune cells comprises at least 85% CAR-expressing immune cells.

[0218] In some embodiments, the population of CAR-expressing immune cells obtained using the above-described method for in vitro sorting of CAR-expressing immune cells exhibits increased in vitro cytotoxic activity compared to an initial (unsorted) cell population. In some embodiments, the in vitro cytotoxic activity is increased by 10%, 20%, 30%, 40%, or 50%. In some embodiments, the immune cells are T cells.

[0219] In some embodiments, mAbs are pre-bound to a support or surface. Non-limiting examples of solid supports may include beads, agarose beads, magnetic beads, plastic well plates, glass well plates, ceramic well plates, columns, or cell culture bags.

[0220] CAR-expressing immune cells to be administered to a recipient can be enriched in vitro from a source population. Methods for expanding a source population may include selecting cells expressing an antigen (such as CD34 antigen) using a combination of: density centrifugation, immunomagnetic bead purification, affinity chromatography, and fluorescence-activated cell sorting.

[0221] Flow cytometry can be used to quantify specific cell types within a cell population. Typically, flow cytometry is a method used primarily by optical means to quantify the components or structural characteristics of cells. Because different cell types can be distinguished by quantifying structural characteristics, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture.

[0222] In some embodiments, the method used to sort CAR-expressing T cells is magnetic activated cell sorting (MACS). Magnetic activated cell sorting (MACS) is a method for separating cell populations based on surface antigens (e.g., CD molecules) of various cell populations using superparamagnetic nanoparticles and columns. MACS can be used to obtain pure cell populations. Cells in a single-cell suspension can be magnetically labeled with microbeads. The sample is applied to a column composed of ferromagnetic spheres,The spheres are coated with a cell-friendly coating, allowing for rapid and gentle cell separation. Unlabeled cells pass through, while magnetically labeled cells remain within the column. The flow-through can be collected as an unlabeled cell fraction. After a washing step, the column is removed from the separator, and the magnetically labeled cells are eluted from the column.

[0223] Detailed protocols for purifying specific cell populations such as T cells can be found in the following literature: Basu S et al. (2010). (Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp. (41): 1546).

[0224] In some embodiments, the pharmaceutical compositions and therapies are formulated by harvesting cells from a culture medium firstly from cells, as described in the detailed specification (pages 79 / 84, CN 121532650 A), then washing and concentrating the cells in a therapeutically effective amount in a suitable medium and container system (“pharmaceutically acceptable” carrier). Suitable infusion media can be any isotonic formulation, typically physiological saline, Normosol™ R (Abbott), or Plasma-Lyte™ A (Baxter), but may also utilize 5% dextran aqueous solution or Ringer's lactate. The infusion media may be supplemented with human serum albumin.

[0225] In embodiments, the desired therapeutic amount of cells in the composition is typically at least two cell types (e.g., at least one CD8+ central or stem cell memory T cell and at least one subset of CD4+ helper T cells; or two or more CD8+ central or stem cell memory T cells; or two or more subsets of CD4+ helper T cells), or more typically greater than 10² cells, and up to and including 10⁶, up to and including 10⁷, 10⁸, or 10⁹ cells, and may be greater than 10¹⁰ cells. The number of cells will depend on the intended use of the composition and the type of cells included in the composition. The desired cell density is typically greater than 10⁶ cells / ml and typically greater than 10⁷ cells / ml, typically 10⁸ cells / ml or greater. A clinically relevant number of immune cells can be allocated to multiple infusions, cumulatively equal to or greater than 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, or 10¹² cells. In some aspects of this disclosure, particularly because all infused cells will be redirected toFor a specific target antigen, a lower number of cells can be administered, in the range of about 10⁵ / kg or about 10⁶ / kg (10⁶–10¹¹ / patient). CAR therapy can be administered multiple times at doses within these ranges. For patients undergoing therapy, the cells can be autologous, allogeneic, or xenogeneic.

[0226] The CAR-expressing cell populations of this disclosure can be administered alone or as pharmaceutical compositions in combination with diluents and / or other components (such as IL-2 or other cytokines or cell populations). The pharmaceutical compositions of this disclosure may comprise cell populations (such as T cells) expressing CAR or TCR as described herein, said cell populations in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions may contain buffers, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates, such as glucose, mannose, sucrose, or dextran, mannitol; proteins; peptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of this disclosure are preferably formulated for intravenous administration.

[0227] Pharmaceutical compositions (solutions, suspensions, etc.) may include one or more of the following: sterile diluents, such as water for injection, saline solutions (preferably physiological saline, Ringer's solution, isotonic sodium chloride), non-volatile oils (such as synthetic monoglycerides or diglycerides), polyethylene glycol, glycerol, propylene glycol or other solvents that can be used as solvents or suspension media; antibacterial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetate, citrate or phosphate; and agents for adjusting tension, such as sodium chloride or dextran. Parenteral preparations can be packaged in ampoules, disposable syringes, or multi-dose vials made of glass or plastic. The injectable pharmaceutical composition is preferably sterile.

[0228] Methods for treating diseases or disorders, including cancer and autoimmune diseases, are provided. In some embodiments, this disclosure relates to generating a T-cell-mediated immune response in a subject, including administering an effective amount of the engineered immune cells of this application to the subject. In some embodiments, the T-cell-mediated immune response targets one or more target cells. In some embodiments, the engineered immune cells comprise a chimeric antigen receptor (CAR). The CAR-containing immune cells of this disclosure can be used to treat CD19-related diseases or disorders and / or BCMA-related diseases or disorders. In some embodiments, the disease or disorder can be an autoimmune disease, including but not limited to lupus, systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, systemic sclerosis, scleroderma, and myositis.

[0229] All references cited herein, including patents, patent applications, papers, textbooks, etc., and those cited therein, are copyrighted.References are incorporated herein by reference in their entirety, if not otherwise stated.

[0230] The following examples are provided for illustrative purposes only. In fact, various modifications to the invention will be apparent to those skilled in the art based on the foregoing description, except for those shown and described herein.

[0231] Examples Example 1 – In the context of adoptive immune cell transfer, the beneficial activities (e.g., activation, proliferation, persistence and / or potency) of CAR T cells engineered to express chimeric antigen receptor (CAR) and chimeric cytokine receptor (CCR) can be enhanced via cytokine-induced cytokine receptor signaling (also known as signal 3). Current methods for signal 3 include combining CAR T cell therapy with systemic infusion of recombinant cytokines / cytokine mimics, and engineering CAR T cells to secrete / express cytokines extracellularly, but these methods have drawbacks, such as the risk of systemic toxicity. In an alternative approach, a constitutively active chimeric cytokine receptor (CACCR) can be used to enhance signaling 3 (see US20200291090A1, which is incorporated herein by reference in its entirety). An exemplary CACCR is designed using a sequence from the thrombopoietin receptor (TpoR). TpoR is capable of activating the JAK-Stat signaling pathway and signals as a homodimer receptor. In this embodiment, immune cells are engineered to express a CD19-specific CAR and a constitutively active chimeric cytokine receptor (CACCR).

[0232] CAR-T cells comprising an exemplary CD19 CAR with a CD19-targeted 4G7 scFv coupled to the 4-1BB and CD3z signaling domains are selected for further engineering of the CACCR. (See, for example, US Patent 10,874,693, which is incorporated herein by reference in its entirety). CD19-specific CAR-T cells co-expressing a CACCR consisting of a truncated IL2Rb tail are generated. CAR-T cells containing an exemplary BCMA CAR and the same CACCR were also selected for testing, the BCMA CAR carrying a BCMA-targeted P5A2 scFv coupled to the 4-1BB and CD3z signaling domains (see, for example, published U.S. Application No. US20210260118A1, which is incorporated herein by reference in its entirety).

[0233] Figure 1A shows a schematic diagram of engineered constitutively active chimeric cytokine receptors. Figure 1B shows a schematic diagram of lentiviral vectors for co-expressing constitutively active chimeric cytokine receptors and anti-CD19 CARs. Anti-CD19 CARs encoding SEQ ID NO: 335 (see Table 3) and SEQ ID NO:Constructs of CACCR 343 (see Table 4).

[0234] Figure 1C shows a schematic diagram of lentiviral vectors for co-expression of constitutively active chimeric cytokine receptors and anti-BCMA CAR. Constructs encoding anti-BCMA CAR (Table 3) containing SEQ ID NO: 342 and / or CACCR (Table 4) containing SEQ ID NO: 343 were used.

[0235] In an exemplary protocol for preparing lentiviruses encoding CACCR and CD19 CAR, HEK293T cells were plated at 450,000 cells / mL in 2 mL of DMEM (Gibco) supplemented with 10% FBS (Hyclone) in each well of a 6-well plate one day before transfection. On the day of transfection, lentivirus was prepared as follows: 1.5 μg psPAX2 lentiviral packaging vector, 0.5 μg pMD2G, and 0.5 μg appropriate transfer CAR vector were mixed together in 250 μL Opti-MEM (Gibco) per well of a 6-well plate (“DNA mixture”). 10 μL of Lipofectamine 2000 (Invitrogen) in the 250 μL Opti-MEM was incubated at room temperature for 5 minutes, and then added to the DNA mixture. The mixture was incubated at room temperature for 20 minutes, and a total volume of 500 μL was slowly added to the side of the wells containing HEK293T cells. One day after transfection, the culture medium for HEK293T cells in each well of the 6-well plate was replaced with 2 mL / well of T cell transduction medium (i.e., X-Vivo-15 supplemented with 10% FBS). Two days post-transfection, lentiviral supernatant was harvested from HEK293T cells and passed through a 0.45-micron filter (EMD Millipore) to remove cell debris. The crude lentiviral supernatant was then used directly for T cell transduction. On day 0, purified T cells were activated in Grex-24 plates (Wilson Wolf, catalog 80192M) in X-Vivo-15 medium (Lonza) supplemented with 100 IU / mL human IL-2 (Miltenyi Biotec), 10% FBS (Hyclone), and human T TransAct (Miltenyi Biotec, catalog 130-111-160, 1:100 dilution). On day 2, T cells were resuspended at 500,000 cells / mL in T cell transduction medium and transduced in Grex-24 plates with an equal volume of crude lentiviral supernatant and 100 IU / mL human IL-2. On day 5, the used medium was replaced with T cell expansion medium (i.e., supplemented with 5% human AB serum (Gemini)).CAR-T cells expressing CACCR were fed with X-Vivo-15 (Bio) and 100 IU / mL human IL-2. Control CAR-T cells lacking CACCR were then expanded in 100 U / mL human IL-2 alone or 100 U / mL human IL-2 and 10 ng / mL human IL-15 (Miltenyi Biotec). Cells were expanded into larger G-Rex containers (Wilson Wolf) as needed using T cell expansion medium and appropriate concentrations of recombinant cytokines. On day 13, cells were stained with a Zombie NIR fixation viability kit (Biolegend), labeled with a BUV395-conjugated CD3 antibody (Biolegend) and an anti-idiotype antibody specific to P5A2 scFv, and then FACS sorted to enrich CAR+ T cells. The sorted CAR+ T cells were then cultured in Grex-24 plates in T cell expansion medium for another 2 days, wherein the CACCR CD19 CAR+ T cells were kept in the absence of exogenous cytokines, and wherein the sorted control CAR+ T cells were kept in the absence of exogenous cytokines and treated with 100 U / mL human IL-2 or 10 ng / mL human IL-15. On day 15, live CAR+ T cells were enriched using the Easy Sep Dead Cell Removal Kit (StemCell Technologies), and the cell pellet was flash-frozen for subsequent RNA extraction and NanoString gene expression analysis (Human CAR-T Panel; NanoString Technologies).

[0236] Example 2 – Detection of CACCR in CAR T cells after stimulation for co-culture settings for CAR T cell stimulation. Two different CAR T cell drug product batches were used as effector cells in this experiment: a) PBMCs were used as starting material to provide cells engineered to express CD19-specific CAR and CACCR (batch 02), and b) CD4 / CD8+ T cells were used as starting material to provide cells engineered to express CD19-specific CAR and CACCR (batch 04). Both CAR T cell drug product batches were engineered from the same donor. Cells from both CAR T cell drug product batches were stimulated at 2.5 μg / ml with irradiated DGL (Daudi cells purchased from ATCC (CCL-213™), engineered with GFP-luciferase and irradiated for assay) or CD19-Fc (Acro bio, USA). Both effector cells were thawed and cultured at 1E6 cells / ml in X-vivo medium containing 10% FBS. Irradiated DGLs were then...A 2:1 effector cell to target cell ratio was added to the culture. After setup, co-culture samples were taken at 20, 24, and 48 hours for Western blotting and flow cytometry.

[0237] Intracellular staining of P2A using flow cytometry. Harvested cells were stained with CD19-specific CAR anti-idiotype antibody PE (Acro Biosystems) and FVS780 (BD Bioscience) in flow cytometry staining buffer (554656, BD). Cells were fixed and permeabilized using FOXP3 transcription factor staining buffer (00-5523-00, eBioscience) according to protocol. Typically, cells were fixed at room temperature (RT) for 20 min using fixation / permeabilization buffer and stained with P2A-APC (NBP2-59627AF647, Novus Bio) in permeabilization buffer at RT for 30 min. Cells were resuspended in staining buffer and analyzed using an LSR Tortessa™ Cell Analyzer (BD Bioscience). Data were analyzed using FlowJo 9.2 software (Tree Star, Inc.).

[0238] As described above, CAR T cell drug products engineered to express CD19-specific CAR and CACCR were incubated with or without IR-DGL. As shown in Figure 2, cells were harvested at 24 hours (Figure 2A) or 48 hours (Figure 2B) and stained with CD19-specific CAR anti-idiotype antibody PE (Acro Biosystems) and FVS780 (Live / Dead activity staining agent), and then fixed with intracellular staining against P2A using transcription factor staining buffer. P2A and CAR+ double-positive cell populations were gated from single-peak live cells under different culture conditions.

[0239] Figure 3 shows the results of further experiments in which cells were incubated with (Figure 3A) or without (Figure 3B) CD19Fc or IR-DGL. Cells were harvested at 24 hours and stained with CD19-specific CAR anti-idiotype antibody PE (see US20200331998A1, which is incorporated herein by reference in its entirety) (custom-made from Biolegend) and FVS780 (Live / Dead viability staining agent), and then fixed with transcription factor staining buffer for intracellular staining against P2A (instructions for use on pages 82 / 84, CN 121532650 A). P2A+ and CAR+ double-positive cell populations were gated from single-peak live cells from different culture conditions.

[0240] P2A detection was performed using Western blot. HEK293T cells transfected with BCMA CAR+ CACCR were used as...Positive controls for P2A protein detection were used. Cell lysates of 0.2E6 cells / µL were prepared for all samples using a mixture of M-PER buffer, protease inhibitor, and reducing agent. 0.26E6 cells from the positive control and 2.6E6 cells from other samples were loaded into 10% Bis-tris gels. Primary antibodies were prepared using a mixture of 1:200 of 2A peptide (3H4) antibody (Novsubio, catalog number NBP2-59627) and 1:1000 of β-tubulin (Cell Signaling, catalog number 2128L). Secondary antibodies were prepared using a mixture of 1:5000 of IRD-800CW goat anti-rabbit IgG (LI-COR, catalog number 926-32211) and IRD-680CW goat anti-mouse IgG (LI-COR, catalog number 926-68070). The blots were visualized using Odyssey CLx. Table 6 lists the samples by lane of the protein blot.

[0241] Table 6

[0242] As shown in Figure 4, tubulin is shown in the 50 kDa band (see upper arrow) and used as a technical control. P2A protein is shown in the 24.3 kDa band (see lower arrow). P2A protein was detected in the positive control and stimulated samples, shown in lanes 1, 2, 3, 4, 6, 7, and 8. P2A protein was not detected in the unstimulated samples, shown in lanes 5 and 9.

[0243] CAR T cells containing anti-BCMA CAR with P5A2 scFv and expressing CACCR (see Example 1 and Table 5 above) were treated with PMA + ionomycin (P+I) to observe the detection level of CACCR. CAR T cells containing anti-BCMA CAR with P5A2 scFv but not expressing CACCR (see Example 1 and Table 5 above) were included as a negative control.

[0244] The following samples listed in Table 7 were tested.

[0245] Table 7

[0246] Frozen whole blood with EDTA as an anticoagulant was used (Stem Cell Technologies). Frozen CAR T cell batches were used (anti-BCMA: 14e6 CAR+ cells / ml in 1 ml; anti-BCMA + CACCR: 40e6 CAR+ cells / 2 ml – see Table 8). Frozen-thawed CAR T cells were adulterated into frozen-thawed whole blood (WB). 10% CAR+ cells were found in live whole blood cells. Specification 83 / 84 pages 86 CN 121532650 A

[0247] Table 8

[0248] Detection of anti-BCMA CARs carrying P5A2 scFv using anti-idiotypic antibodies against CARs (see published U.S. Patent Application No. 20240101710A1, which is incorporated herein by reference in its entirety).

[0249] Anti-BCMA CAR was detected in all samples (data not shown). CACCR was detected via P2A in a WB / CAR mixture a) unstimulated and stained after mixing cells; or b) stimulated with PMA + iomycin for 24 h before staining. Cells were stained for viability and surface markers, followed by fixation / permeabilization for intracellular P2A staining. As shown in Figures 6A-6B, CCR was detected in P+I stimulated samples (right inset) using the anti-P2A antibody P2A-APC (NBP2-59627AF647, Novus Bio), but not in unstimulated samples (left inset). As expected, CACCR was not detected in any sample (data not shown). Instruction manual page 84 / 84, page 87 CN 121532650 A, Figure 1; Instruction manual figure 1 / 9 page, page 88 CN 121532650 A, Figure 2A; Instruction manual figure 2 / 9 page, page 89 CN 121532650 A, Figure 2B; Instruction manual figure 3 / 9 page, page 90 CN 121532650 A, Figure 3A; Instruction manual figure 4 / 9 page, page 91 CN 121532650 A, Figure 3B; Instruction manual figure 5 / 9 page, page 92 CN 121532650 A, Figure 4; Instruction manual figure 6 / 9 page, page 93 CN 121532650 A, Figure 5; Instruction manual figure 7 / 9 page, page 94 CN 121532650 A, Figure 6A; Instruction manual figure 8 / 9 page, page 95 CN 121532650 A, Figure 6B; Instruction manual figure 9 / 9 page, page 96 CN 121532650 A

Claims

1. An in vitro method for detecting bicistronic expressed polypeptides in chimeric antigen receptor (CAR) T cells, the method comprising: a) Contact the CAR T cells with an exogenous drug, wherein the CAR T cells contain a polynucleotide expressing the bicistronic polypeptide, a linker peptide, and another polypeptide, wherein the linker peptide is located at the C-terminus of the bicistronic polypeptide; as well as b) After step a), the linker peptide is detected, thereby indicating the presence of the bicistron-expressed polypeptide in the CAR T cells.

2. The method of claim 1, wherein the bicistronic expressed polypeptide comprises a transmembrane domain.

3. The method of claim 1, wherein the bicistronic expressed polypeptide is a membrane protein containing a transmembrane domain.

4. The method of claim 2 or 3, wherein the bicistronic expressed polypeptide further comprises an intracellular domain.

5. The method of any one of claims 1-4, wherein the linker peptide is located at the C-terminus of the bicistron-expressed polypeptide.

6. The method of any one of claims 3-5, wherein the linker peptide is located at the C-terminus of the intracellular domain.

7. The method of any one of claims 1-6, wherein the bicistronic expressed polypeptide further comprises an extracellular domain.

8. The method of any of the preceding claims, wherein the linker peptide is heterologous to the bicistronic expressed polypeptide.

9. The method of any one of claims 4-8, wherein the linker peptide is adjacent to the intracellular domain of the bicistron-expressed polypeptide.

10. The method of any one of claims 4-9, wherein the intracellular domain is an intracellular signal transduction domain.

11. The method of any one of claims 1-10, wherein the additional polypeptide is CAR.

12. The method of any of the preceding claims, wherein the exogenous agent is selected from small molecule reagents and target molecules, wherein the CAR specifically binds to the target molecule.

13. The method of claim 12, wherein the small molecule reagent stimulates the production of cytokines in the CAR T cells.

14. The method of claim 12 or 13, wherein the small molecule reagent comprises phorbol myristate acetate (PMA) and / or ionomycin.

15. The method of claim 12, wherein the target molecule is a soluble target molecule.

16. The method of claim 12, wherein the target molecule is expressed on the surface of the target cell.

17. The method of claim 16, wherein the contact comprises contacting the CAR T cells with the target cells.

18. The method of claim 16 or 17, wherein the target cell is an inactivated target cell.

19. The method of claim 15, wherein the contacting step comprises contacting the CAR T cells with the soluble target molecule.

20. The method of any of the preceding claims, wherein the linker peptide is cleavable.

21. The method of claim 20, wherein the linker peptide is cleaved by an enzyme.

22. The method of claim 20, wherein the linking peptide is a self-cleaving peptide.

23. The method of claim 22, wherein the self-cleaving peptide is a P2A or T2A peptide.

24. The method of any of the preceding claims, wherein the linker peptide comprises the amino acid sequence shown in any one of SEQ ID NO: 305-320.

25. The method of any of the preceding claims, wherein the bicistronic expressed polypeptide is a chimeric cytokine receptor (CCR), wherein the CCR comprises a transmembrane domain and an intracellular domain.

26. The method of claim 25, wherein the CCR further comprises an extracellular domain.

27. The method of claim 25, wherein the CCR does not include an extracellular domain.

28. The method of claim 25 or 26, wherein the CCR is an induced CCR.

29. The method of any one of claims 25-27, wherein the CCR is a constitutively active CCR.

30. The method of any of the preceding claims, wherein the detection step comprises detecting the linker peptide by flow cytometry and / or Western blotting.

31. The method of claim 8, wherein the bicistronic expressed polypeptide further comprises an intracellular domain.

32. The method of claim 31, wherein the linker peptide is located at the C-terminus of the intracellular domain.

33. An in vitro method for analyzing a CAR T cell population, wherein the CAR T cells express a bicistronic expressed polypeptide, a linker peptide, and CAR, the method comprising: a) Contact the sample of the CAR T cell population with the exogenous drug; as well as b) Detect the bicistronic expressed polypeptide in the sample after the contact step.

34. The method of claim 33, wherein the linker peptide is attached to the C-terminus of the bicistronic expressed polypeptide, and the step of detecting the bicistronic expressed polypeptide includes detecting the linker peptide in the sample.

35. The method of claim 33 or 34, further comprising: c) Analyze whether a predetermined level or more of the bicistronic expressed polypeptide is detected in the sample.

36. The method of claim 35, wherein the predetermined level is the presence of the linker peptide in at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50% of the CAR T cells in the sample.

37. The method of any one of claims 33-36, wherein the CAR T cell population constitutes a CAR T cell drug substance or a CAR T cell drug product.

38. The method of claim 37, further comprising: d) If a predetermined level or more of the bicistronic expressed polypeptide is detected in the sample, the CAR T cell population is formulated to form a drug product; and optionally e) the drug product is frozen.